Download Annual Report for pdf.qxd

CASEY
EYE
INSTITUTE
C
E
L
E
E
D
U
C
I
N
N
O
B
R
A
A
T
E
V
A
T
ANNUAL
T
E
E
REPORT
2002
C A S E Y
E Y E
I N S T I T U T E
A N N U A L
R E P O R T
2 0 0 2
TABLE OF CONTENTS
The Casey Eye Institute
Letter from the Chairman
page 1
(CEI) is an academic
Research To Prevent Blindness
page 2
regional eye center
Cornea
page 4
dedicated to preventing
Donor Profile: The Pettis
page 6
blindness through
Genetics
page 7
research, and to
Glaucoma
page 8
bringing the highest
Uveitis and Inflammatory Diseases
page 10
quality patient care
Retina/Macular Degeneration
page 12
and advanced technology
Donor Profile: Bula “Bea” Arveson
page 14
to the Pacific Northwest.
Low Vision
page 15
Ophthalmic Plastic and
Reconstructive Surgery
page 16
Pediatrics
Elks Children’s Eye Clinic
page 18
Neuro-Ophthalmology
page 20
Casey Ophthalmic Associates
page 21
Clinical Trials
page 22
Honors and Awards
page 29
Clinical and Research Faculty
page 30
Fellows and Residents
page 33
Residency Program
page 33
Contributions to the Casey Eye Institute page 34
1
Dear Friends:
In this, our first annual report, we celebrate our successes and share the good news
of innovation in science and clinical care. We also mark a new era in Casey history: in
2001, we celebrated ten years in our own freestanding institute, and last year we
kicked off a $26 million campaign to expand the building.
Our rapid growth makes it imperative to enlarge our facility. Since we first opened our
doors in 1991, our federal research funding has more than tripled. Funding from the
National Institutes of Health places OHSU in 9th place among all institutes receiving
support from the National Eye Institute. Clinical growth has been extraordinary –
a 100% increase in outpatient visits since 1991 (over 44,000 in 2002). Our staff has
increased to 270 people, most still housed in the original, 120,000-square foot building.
This report highlights many of the accomplishments of our researchers and educators.
Their achievements span a gamut that ranges from unraveling the genetic mysteries
of glaucoma and macular degeneration, the leading causes of visual loss among the
elderly in this country, to advances in online education. There are many numbers that
could be quoted. For example, our uveitis service, a small division in this department,
has seven NIH grants. Our residency training program is more sought-after than ever.
We now have 80 applicants for every available position. But an academic department
is much more than numbers or specific achievements. It is a community which hopefully
provides a unique constellation of resources in a supportive and collaborative environment that advances our knowledge, cares for the sick and improves our future.
Our greatest accomplishment at Casey is developing the type of community that I just
described. I am particularly proud to report that the Casey spirit is thriving.
It embodies the values of academic medicine that we all cherish. It promises us a
bright future.
I want to conclude this introductory statement with comments about a venture that is a
major source of pride for me. In 1999, we formed a partnership with Legacy’s Devers
Eye Institute on the Good Samaritan campus in northwest Portland, emphasizing
cooperation rather than competition. Together, we can better allocate scarce
resources and benefit the entire region. This affiliation adds to our talent pool and
enriches the residency experience. We share an eye bank and jointly host Grand
Rounds, strengthening our commitment to learning, patient service and the local
community.
2002 was a watershed year in the history of the Casey Eye Institute, one whose promise
will be fulfilled in the years ahead. As you read, I know you will come to share our
sense of excitement at what the future holds.
Sincerely,
Joseph E. Robertson, M.D., M.B.A.
Professor and Chairman
2
RPB ADDS CRITICAL FUNDING
Research to
Prevent
Blindness is the
Institute has become one
world’s leading organization
of the leading eye research
in support of eye research.
facilities in the world.
foresight has proven
prophetic: The Casey Eye
In 1982, New York-based
RPB selected the Department
This interactive relationship
of Ophthalmology in the
is further evidenced by
Oregon Health & Science
ongoing collaboration with
University as its seventh
RPB. RPB has awarded the
regional eye center, and
Casey Eye Institute nearly
played a major role in con-
$3 million over the years.
ceiving and developing the
According to Joe Robertson,
Casey Eye Institute. This
M.D., chairman of the
included mobilizing financial
Department of Ophthalmology,
resources and procuring
“Many of our advances can
essential laboratory space,
be linked directly to our
equipment and scientific
long-term relationship with
personnel.
RPB.”
According to RPB chair-
RPB funding, both restrict-
man David Weeks, OHSU
ed and specific grant
was chosen because its
awards, has allowed the
ophthalmology department
department to pursue
had the talent to attract,
research in uveitis, glauco-
train and inspire
ma, macular degeneration,
researchers of the highest
cataracts, and retinal and
caliber. And now, more
corneal diseases.
than 20 years later, Weeks’
(l to r) David Weeks,
Dr. Kenneth Swan and
Dr. Fritz Fraunfelder
during the Casey’s construction.
Winner of the prestigious Career
Development Award from RPB,
Justine Smith, M.B.B.S., Ph.D.,
is studying uveitis. Using new molecular
biology technology known as microarray,
she initiated a project designed to show
how Toxoplasma gondii influences the
gene expression of cells within the eye
during toxoplasmic retinochoroiditis.
3
John C. Morrison, M.D., received
the Lew Wasserman Award from
RPB, and is studying the cellular
response of the optic nerve head.
His findings have led to a hypothesis
that explains why early damage in
human glaucoma characteristically
occurs in the superior and inferior
optic nerve head.
William D. Mathers, M.D., recipient of
the RPB Physician-Scientist Award,
investigates the interaction of the surface
of the eye and the regulation of tear
production in the lacrimal gland.
2002 recipient of the Robert E. McCormick
Scholar Award, Tim Stout, M.D., is developing ways to genetically modulate the process
of intraocular cellular proliferation. This is
done to prevent the blinding complications
of diseases such as age-related macular
degeneration, proliferative diabetic
retinopathy, retinopathy of prematurity,
and post-cataract extraction posterior
capsular opacification.
Mary Wirtz, Ph.D., an RPB Dolly Green
Scholar, is using RPB funding to support
several glaucoma genetic projects.
By analyzing DNA samples, Wirtz and her
team mapped the third and sixth gene of
the six now associated with glaucoma.
RPB Senior Scientific
Investigator Ted Acott,
Ph.D., focuses on understanding how the trabecular
meshwork senses intraocular
pressure changes and
responds to maintain it
within acceptable levels to
avoid glaucoma in the
healthy eye. Understanding
the normal functions of this
tissue should provide keys
for correcting the changes,
which result in elevated
intraocular pressure and
trigger optic nerve damage
in glaucoma.
Stephen Planck, Ph.D., recipient
of the James S. Adams Scholar
Award from RPB, is using a
multifaceted approach to studying
ocular inflammation. His team is
culturing cells from the lining of
the blood vessels and studying their
role as gatekeepers for the white
blood cells. Videomicroscopy is used
to track the different kinds of cells
that initiate and execute immune
and inflammatory responses.
4
CORNEA
Stem cell transplants give the gift of sight.
Larry F. Rich, M.D.
Cornea service director
effectiveness of antibiotics
Larry F. Rich, M.D. treats
in treating acanthamoeba.
some forms of corneal
By allowing researchers to
disease with epithelial stem
watch cells interact, the
cell transplants. The trans-
microscope can speed
plants can help regenerate
assessment of whether—
cells—and sight—damaged
and which—antibiotics
by disease, adverse drug
work against disease. We
reactions, or burns. Dr. Rich
also use confocal
recalls a gift of epithelial
microscopy in refractive
cells from one identical
surgery (to determine the
twin to another that allowed
thickness of LASIK flaps),
a woman to regain sight
to diagnose infectious
after 30 years of blindness.
disease and to collaborate
Used as a precursor to
on immunologic research
whole-cornea grafts, prolif-
with James T. Rosenbaum,
erating stem cells can
M.D., director of Casey’s
sometimes even preclude
uveitis service.
the need for a transplant,
and grafts of stem cells
Casey Eye Institute’s
and conjunctival tissue can
cornea service is home to
keep pterygia from recurring.
the National Registry of
Drug-Induced Ocular Side
Damien Macaluso, M.D.
Another tool for treating
Effects, the only resource
corneal disease is Casey’s
of its kind in any subspe-
confocal microscope,
cialty. Founded by F.T.
which William Mathers, M.D.
“Fritz” Fraunfelder, M.D. in
is using to evaluate the
1976, the Registry went
5
F.T. “Fritz” Fraunfelder, M.D.
Rick Fraunfelder, M.D.
online in 2002 under the
The Casey cornea team
available on the Web.
direction of Rick Fraunfelder,
continues working to make
Special technology will
M.D. (www.eyedrugreg-
refractive surgery safer
make lectures easy to
istry.com). The father-son
and more successful,
download even without a
team has written extensive-
using our substantial
high-speed connection,
ly on ocular pharmacology,
patient database to evalu-
and a series of questions
recently reviewing side
ate and improve outcomes.
at each lecture’s end will
effects of high-profile drugs
In bench research, Dr.
allow viewers to earn CME
like Gleevec and Zyrtec.
Mathers and Yuan Fang,
credits for virtual atten-
Log on to the Registry to
M.D., Ph.D. are studying
dance. According to
report cases or request
molecular interactions
Dr. Macaluso, not only
information on a particular
between the lacrimal gland
virtual Grand Rounds but
drug.
and other organ systems,
also Web-based telecon-
working toward a possible
ferences are in Casey’s
Casey is currently the only
genetic explanation for the
future.
site in the country treating
persistent problem of dry
ocular surface tumors with
eye. Damien Macaluso,
liquid nitrogen cryotherapy.
M.D. is also collaborating
At -196°C, tumors are
with Tim Stout, M.D. of our
quickly frozen. “The treat-
retina service on gene ther-
ment is less damaging to
apy for corneal disease.
the eye than radiation,”
notes Rick Fraunfelder, M.D.,
To disseminate the insights
adding that this high-tech
gained in the laboratory
surgery is also quicker and
and clinic, Macaluso plans
more cost-effective than
to make the joint Casey/Devers
other methods.
Eye Institute Grand Rounds
6
Giving Well: The Story of August and Margaret Petti
Owners of the Portland
Casey Eye Institute’s fourth-
landmark Henry Thiele’s
floor atrium, named for the
Restaurant, August Petti and
Pettis, incorporates the
his wife Margaret Thiele Petti
world’s largest glass floor.
sought help at OHSU in the
Made of brilliant blue glass
late 1980s when August’s
blocks, it is a stunning
eyesight began to fail. The
reminder of this generous
pair saw Kenneth Swan,
couple.
M.D. in early 1990. He
referred them to corneal spe-
The Pettis created three
cialist Larry Rich, M.D., who
endowments at Casey:
performed a corneal transplant
that allowed the 98-year-old
‹ The Chair of Ophthalmology
gentleman to regain his sight
in honor of Kenneth C.
and enjoy life again. Later,
Swan, M.D., currently held
Margaret Petti had cataract
by Joseph E. Robertson, M.D.
surgery at Casey, and saw
Michael Klein, M.D., and
‹ The Chair for the
David Wilson, M.D., for
Director of Corneal Service
treatment of her diabetic
in honor of Larry F. Rich,
retinopathy. Both August and
M.D., who holds the chair.
Margaret Petti were also
patients of F.T. “Fritz”
‹ The Research Fund for
Fraunfelder, M.D.
corneal and diabetesrelated diseases.
7
OPHTHALMIC GENETICS CENTER
“We are entering an era of being able to make more precise
diagnosis more quickly through testing at the molecular level.”
Richard Weleber, M.D.
The Ophthalmic Genetics Center at
Many genetically linked syndromes
was diagnosed with retinitis pigmen-
Casey Eye Institute is one of few in
include eye problems in their medical
tosa. However, Smith felt she needed
the country devoted to diagnosing
landscape. In the past, making a
more answers and found Dr. Weleber.
complex genetic diseases with asso-
specific diagnosis was a difficult and
ciated ophthalmic problems.
lengthy process, but that scenario
After extensive testing and exploring
Director Richard Weleber, M.D., is
is changing. As Weleber states,
her family medical history, Weleber
a founding member of the American
“We use laboratories across the
diagnosed autosomal dominant neo-
Board of Medical Genetics. He
country where specialized genetic
vascular inflammatory vitreoretinopathy
offers a unique set of qualifications
tests have been developed,
(ADNIV). The rare disease had been
since he is both a board certified
enabling us to diagnose diseases
traced to one family in Iowa and
ophthalmologist and medical
previously very difficult to pinpoint.”
Ohio. Smith recalled a paternal
geneticist.
Like a master sleuth, Weleber care-
grandfather who had lost vision.
fully assembles all the pieces of the
“Looking for more answers, I called
puzzle. When fitted together, they
a second cousin who is a Midwest
often form a picture of a specific
physician. She explored our family
genetic syndrome.
genealogy and found early family lineage linked to this same family in
Karmen Trzupek, M.S., assists
Iowa.”
Weleber by providing genetic counseling to patients and their families.
Knowing a specific diagnosis, Smith
“Having a genetic counselor is a
will be able to mitigate conditions
great advantage,” Weleber continues,
associated with this disease, includ-
“Often, we are able to establish the
ing a greater likelihood of cataracts
presence of an inherited disease
and glaucoma. She continues,
previously unknown in a family.”
“I have been so impressed seeing
Richard G. Weleber, M.D.
research in action. Even though the
Chrystal Smith, who lives in Juneau,
Casey is two plane flights and two
Alaska, is grateful for Weleber’s
thousand miles away, every visit is
expertise. Two years ago, she
very much worth the effort.”
began experiencing vision loss and
8
GLAUCOMA
John R. Samples, M.D.
Glaucoma model brings closer
understanding of how elevated
pressure causes glaucoma.
CEI researchers are working
Approaching the problem
hard to improve treatment
from a genetic perspective,
for this devastating eye
John Samples, M.D., and
disease, to understand its
Mary Wirtz, Ph.D., have
causes, and ultimately, to
discovered the third and
find a cure.
sixth (out of six) known
John Morrison, M.D., and
genetic loci for open angle
Elaine Johnson, Ph.D.,
glaucoma in a study of
have developed a glaucoma
several large families. The
model that highlights the
third locus, GLC1C, was
focal nature of optic nerve
the first to be clearly delin-
damage, bringing us
eated for adult high-pres-
several steps closer to
sure, open-angle glaucoma.
understanding how elevat-
This study, derived from
ed intraocular pressure
Samples’ practice and
causes glaucoma.
funded by several NEI
Morrison and Johnson
grants, was carried on in
have found a distinct,
both Portland and Greece.
repeatable pattern of injury,
Samples is also working
allowing them to pinpoint
with other collaborators to
the injury site in a specific
determine whether there is
region of the nerve head.
value in testing glaucoma
Morrison’s work was
genes commercially at
recently recognized with
present.
the Lew R. Wasserman
Merit Award for Glaucoma
In another approach to
Research from Research to
elevated IOP, Samples and
Prevent Blindness. He is
Al Eisner, Ph.D., are using
also the recipient of a four-
psychophysical testing to
year NIH grant, “Studies in
evaluate the neuroretinal
Glaucomatous Optic Nerve
damage caused by elevated
Damage.”
IOP and drugs (most
9
John C. Morrison, M.D.
recently, tamoxifen). In
Researchers John Bradley,
from throughout the world.
addition, Samples is
Ph.D., Ted Acott, Ph.D.,
It covers basic science,
collaborating with Paul
and Samples are evaluat-
clinical diagnosis and man-
Knepper, M.D., Ph.D., of
ing it, both in patients and
agement of all forms of
Northwestern University to
in the laboratory, with the
glaucoma, and includes
study specific molecules,
goal of further refining the
important new details on
termed CD44, which are
mechanism by which it
etiology, genetics, and epi-
only elevated in primary
works. In addition,
demiology as well as a dis-
open-angle glaucoma.
Samples is working with a
cussion of neuroprotection.
These molecules seem to
small California company
Samples is presently work-
be highly toxic to the out-
called Glaukos to develop
ing on a book on ophthalmic
flow structures and to reti-
an entirely new type of out-
genetics for W.B. Saunders.
nal and optic nerve cells,
flow device for lowering
as well as to the trabecular
IOP. Clinical trials are
meshwork. He also has a
planned for mid-2003.
meshwork’s extracellular
matrix and is examining the
presence of certain
enzymes (interleukin related kinases, or IRAK) in the
trabecular meshwork associated with reaction to the
cytokines.
co-investigators on “Visual
Adaptation Limits of Age-
longstanding interest in the
effects of cytokines on the
Eisner and Samples are
Related Disease” (the two
Both Morrison and
Samples continue to make
important contributions to
the literature. Working with
Irvin P. Pollack, M.D., of the
Wilmer Eye Institute,
Morrison has edited a new,
comprehensive text,
also hope to begin an NIHfunded study this year on
female hormones and
vision.) Samples, who currently serves on the AAO’s
Technology Assessment
committee as well as the
committee charged with
Glaucoma: Science and
rewriting the association’s
Practice. This textbook,
glaucoma text, is co-direc-
As of this writing, the only
released by Thieme
selective laser trabeculo-
Medical Publishers in
plasty unit in the state of
November 2002, contains
Oregon is housed at the
contributions from more
Casey Eye Institute.
than 35 recognized experts
tor of a national glaucoma
symposium to be held in
Las Vegas in mid-2003.
10
UVEITIS and INFLAMMATORY DISEASES
“Uveitis researchers are looking to the needs of the future.”
Directed by James T.
Rosenbaum, Suhler and
Rosenbaum, M.D., holder
Smith are investigating
of the Edward T.
infliximab (Remicade), a
Rosenbaum Chair in
monoclonal antibody
Inflammatory Diseases, the
against tumor-necrosis factor
service includes co-director
alpha, for treatment of
Eric B. Suhler, M.D., chief
vision-threatening, non-
of ophthalmology at the
infectious uveitis that is
Portland Veterans Affairs
refractory to other systemic
Medical Center; Justine
immunosuppressants.
Smith, M.B.B.S., Ph.D.;
Though Remicade has
Roger George, M.D., and
already been proved effec-
Daryl Kurz, M.D.
tive in the treatment of
Rosenbaum is the current
other systemic inflammatory
president of the American
diseases (such as Crohn
Uveitis Society.
disease and rheumatoid
arthritis), this is the first trial
James T. Rosenbaum, M.D. with his father, Edward T. Rosenbaum, M.D.
The Casey Eye Institute is
of the drug specifically for
an important part of new
ocular inflammation.
uveitis therapy studies.
Patients come from all over
Since 1985 the NIH has
the Pacific Northwest for
generously supported
specialized care, some-
OHSU’s basic research into
times including experimental
the pathogenesis of uveitis
drugs. For example,
and ocular inflammation.
11
Uveitis/Inflammatory Diseases research staff
CEI researchers, including
and Europe. The Casey is
in eye-related research. In
Stephen R. Planck, Ph.D.,
the only center in the world
the past, this program has
were among the first to
to publish on the isolation
convinced several talented
study cytokines and adhe-
and characterization of
scientists to take up oph-
sion molecules in ocular
microvascular endothelial
thalmic research. Faculty
inflammation. CEI is also a
cells from the iris. The
members are also continu-
world pioneer in using
endothelial cell is a gate-
ing their own education:
intravitreal microscopy to
keeper in inflammation,
Smith returns in July from a
watch cells at work in the
and CEI researchers are
research fellowship with
eyes of living rodents and
characterizing its role in
Yvonne DeKozak, M.D.,
people, monitoring immune
uveitis as well as in other
Ph.D., at the Centre de
system activity in and
diseases, such as diabetic
Recherches Biomedical
around individual blood
retinopathy. Finally, we are
des Cordeliers in Paris,
vessels or cells as a dis-
also investigating how a
while Suhler will soon com-
ease progresses.
slight change in a protein
plete his master’s in public
called NOD2 results in
health with an emphasis in
CEI researchers led by
Blau syndrome, a rare,
epidemiology and
Tammy Martin, Ph.D., have
inherited form of uveitis.
biostatistics.
also embarked on a project
to identify the genes that
CEI’s uveitis researchers
increase uveitis risk, col-
are looking to the needs of
lecting family histories and
the future, as Rosenbaum
blood for DNA analysis
administers a training grant
from patients throughout
that supports seven pre-
the United States, Canada
doctoral graduate students
12
MACULAR DEGENERATION TREATMENT
POSSIBILITIES EXPAND
“We will now have the opportunity to deliver
therapeutic genes directly to a patient’s cells.”
Timothy Stout, M.D., Ph.D.
Tim Stout, M.D. (r.) with research staff
“Of all the recent research
to repair eye disease damage.
developments in the realm of
We will now have the opportunity
retinal disorders, the most
to deliver therapeutic genes
exciting is in the field of macular
directly to a patient’s cells.”
degeneration,” states Joseph
Michael Klein, M.D. (l.) with Mitch Schain
Robertson, M.D., M.B.A., pro-
Using this master map of the
fessor and chairman of the
30,000 genes in the human
department of ophthalmology.
body, Casey researchers have
“Five to ten years ago, we had
already pinpointed genes
very limited treatment options.
responsible for macular degen-
Today, we are involved in clini-
eration and glaucoma. As
cal trials exploring multiple
Stout explains, “We know the
modes of therapy that existed
development of many serious
only in our imaginations until
eye diseases is influenced by
now. We can now offer hope of
one or more abnormal genes.
vision stabilization in many of
When we locate all the genetic
our patients and the promise of
players in each disease, we
vision improvement for all
can then look at what goes
seems close at hand.”
wrong inside the cell and work
on altering those chemical
For the first time, researchers
processes at the cellular level,
are learning how to treat eye
halting the disease process
disease at the cellular level.
before it even gets started.”
Tim Stout, M.D., Ph.D., enthusi-
Andreas Lauer, M.D.
astically details how last year’s
Although still in its infancy, the
completion of the Human
ability to deliver therapeutic
Genome Project is impacting
genes directly to the retina will
his life as a retina physician
expand the spectrum of possi-
and researcher. “In the past,
ble treatments for age-related
I have only had mechanical
macular degeneration, or AMD.
tools such as laser or surgery
Nationally, AMD is the leading
13
cause of irreversible vision loss
Stout and Michael Klein, M.D.,
in preventing new blood vessel
in the U.S., currently affecting
are in the early phase of a
growth. It is being compared to
1.7 million people over the age
multi-center clinical trial spon-
photodynamic therapy, a major
of 65. An increasing aging
sored by GenVec, a biotech
medical breakthrough
population is propelling
company developing anti-
approved in the spring of 2000
researchers at Casey Eye
angiogenic drugs designed to
for the treatment of wet AMD.
Institute and other institutions
deliver medication directly to
Although this approach does
across the country to try to
the retina by means of an
not restore vision lost to AMD,
understand the causes and
injection behind the eye.
it can slow the progression of
develop effective treatments for
This approach to treating AMD
the disease.
this often-debilitating disease.
is not completely new.
Beginning two years ago,
Other types of laser treatment
A major underlying cause of
Klein, director of the Macular
are also being studied. Klein
macular degeneration is known
Degeneration Center, began a
and his team are conducting
to be angiogenesis, the growth
study in conjunction with
the Complications of Age-
of unwanted new blood vessels.
Eyetech Pharmaceuticals
Related Macular Degeneration
These can bleed and scar,
involving an investigative drug
Trial (CAPT) to learn if a specif-
damaging light-sensitive cells
named Macugen, also
ic laser treatment can prevent
and destroying a person’s cen-
designed to block new blood
the advanced complications of
tral vision. This same process
vessel growth. An expanded
AMD and the associated vision
occurs in diabetic retinopathy
study is now underway.
loss.
Stout continues, “How these
In tandem with gene therapy,
The most recent faculty addi-
blood vessels grow is a complex
researchers are moving closer
tion to the retina service, Lauer
process. Researchers have
to identifying specific genes
has immersed himself in
isolated 22 different chemicals
responsible for AMD. In the
research as a co-investigator in
encoded in genes responsible
Genetics of AMD study led by
several studies, including the
for growing new blood vessels.
Klein and Dennis Schultz,
Age-Related Eye Disease
We know gene-containing pro-
Ph.D., the DNA of more than
Study (AREDS) at Devers Eye
teins like vascular endothelial
100 families affected by the
Institute. He also serves as the
growth factor (VEGF) promote
disease is being analyzed.
residency program coordinator.
vascular growth and others like
Four years ago, Klein and his
pigment epithelial derivative
team localized the first gene
Interest in the carotenoids,
factor (PEDF) inhibit growth. In
linked to AMD in several mem-
lutein and zeaxanthin, pig-
a healthy eye, these two factors
bers of a large family.
ments found in green, yellow
and retinopathy of prematurity.
remain in balance. In the dis-
and orange fruits and vegeta-
eased eye, biological signals
Klein, along with Andreas
bles evolved into two studies.
instruct new vessels to grow,
Lauer, M.D., is also conducting
Klein and his team are con-
overpowering those that would
a study of the steroid anacor-
ducting the Carotenoid Study,
typically prevent the process.”
tave acetate and its effectiveness
sponsored by the Foundation
14
Macular Degeneration
Treatment (continued)
Fighting Blindness, to determine
whether consuming large amounts
Generosity Advances
Macular Degeneration Research
of carotenoid-containing foods will
possibly decrease the risk of devel-
director of the center and Arveson’s
oping wet AMD. The Carotenoids
physician. “The center has already
in Age-Related Eye Disease Study
been instrumental in advances in drug
(CAREDS), sponsored by NIH as
therapy, genetics research and nutrition
part of the Kaiser Women’s Health
to prevent and treat this disease, but
Initiative, is looking at how environ-
this kind of transformative gift can lead
mental factors such as diet, sunlight
to greater things.”
exposure and family history may
influence AMD.
Bula “Bea” Buck
Arveson’s voice sparkled with
Born in 1902 to a pioneering family in
David Wilson, M.D. and Robert
resolve about helping researchers find
Arveson in 1925 and moved to
Watzke, M.D., are nearing completion
a cure for age-related macular degen-
Portland. Her husband, who died in
of the NIH-sponsored Collaborative
eration, the leading cause of severe
1988, spent 35 years as vice president
Ocular Melanoma Study (COMS),
vision loss in people older than 65.
and western manager of U.S. Epperson
which began in 1987. Wilson is
Because she and two siblings had
Underwriting Company. Arveson devoted
also the principal investigator and
experienced vision loss from AMD, she
much of her life to public service, vol-
a writing committee member of the
had a personal interest in this disease.
unteering for organizations such as
Submacular Surgery Trial (SST),
During a 1995 interview, she spoke of
Head Start and the Portland Veterans
which will conclude in September
her desire to assist researchers in find-
Affairs Medical Center. In the early
2003. In conjunction with Oculex,
ing a cure for AMD. “Something has to
1930s, she was instrumental in getting
he is testing a new delivery system
be done and I think OHSU researchers
the first black woman admitted to the
with a self-dissolving pellet implanted
can do it. I want to help make that possible.”
nursing program at the University of
under the conjunctiva designed to
treat cystoid macular edema. In
Idaho Falls, Idaho, she married Charles
Oregon Medical School, now the
Although Arveson died last year at the
OHSU School of Medicine.
addition, Wilson recently completed
age of 98, she left a clear directive with
his thesis for membership in the
a $5 million gift to the OHSU Casey
Bea Arveson spent a lifetime caring for
American Ophthalmological
Eye Institute, establishing the Bula
others. Her generous legacy will continue
Society involving glucose uptake in
Buck and Charles C. Arveson
to make a huge difference in conquer-
the inner retina.
Endowment Fund. This is one of the
ing AMD, a disease that can greatly
largest private gifts ever given to help
impact a person’s vision and subse-
fight macular degeneration.
quently their quality of life. Sigrid
Button, a former administrator of the
David Wilson, M.D.
A patient at Casey for more than a
Casey Eye Institute recalls Arveson.
decade, Arveson also served on the
“She always had tremendous foresight
board of its Macular Degeneration
and understood this gift would be the
Center. “Her generous gift will allow us
very best investment for her own family
to dramatically accelerate our
as well as reaching many lives far into
research,” said Michael Klein, M.D.,
the future.”
15
MAKING THE MOST OF LOW VISION
“It is essential to find ways to help (patients) maintain a satisfying lifestyle...”
John Boyer, O.D.
The Casey Eye Institute’s
“People tend to scale down
Low Vision Rehabilitation
their lives when faced with
Clinic provides an invalu-
vision loss, which can be
able service to patients
devastating,” Boyer notes.
referred by ophthalmolo-
“It is essential to find ways
gists and optometrists in
to help them maintain a
Oregon and from many
satisfying lifestyle and
other states. Clinic director
activity level.” Something
John Boyer, O.D., evalu-
as simple as proper light-
ates patients with low
ing or as complex as the
vision as a supplement to
latest video technology can
their medical ophthalmolo-
help patients return to
gy needs. The clinic helps
work, school or daily activi-
patients find ways to pur-
ties. Even more importantly,
sue their interests and
low vision rehabilitation
activities despite the need
helps people recover the
for vision assistance.
independence, autonomy
and optimism they may
have lost.
16
OPHTHALMIC PLASTIC and RECONSTRUCTIVE SURGERY
“Our research is ultimately all done to benefit our patients.”
Roger A. Dailey, M.D.
Roger Dailey, M.D. (r.) and fellow, Stan Saulny, M.D.
Our oculoplastics division
is ultimately all done to benefit
continues to lead the way in
our patients.” On the academic
both cosmetic and reconstructive
side, Dailey is coauthor, with
procedures. Roger A. Dailey,
John Wobig, M.D., of
M.D., has developed new tech-
Oculoplastic Surgery: Face,
niques in lacrimal surgery
Lacrimal System, and Orbit,
(Instat for hemostasis), ptosis
expected from Thieme Medical
surgery (transconjunctival fascia
Publishers in the fall of 2003.
late sling), and orbital surgery
(LeFort I Orbitotomy). He also
recently designed a globe
retractor (now sold by Bausch
& Lomb) used in optic nerve
sheath decompression and
orbital tumor removal.
Currently, he is working with a
company called Ocular
Concepts to produce irisenhanced conformers for postoperative enucleation patients,
with collaborative trials underway. In addition, clinically
based research continues to
flourish at CEI. Allergan
Pharmaceuticals is sponsoring
a new clinical trial of Botox, set
to begin in early 2003. “After
all,” notes Dailey, “our research
Lester T. Jones, M.D.
Holder of the Lester T. Jones
Chair of Ophthalmic Facial
Plastic Surgery - the only
endowed chair in oculoplastics
in the country - Dailey is also
preceptor of CEI’s two-year,
ASOPRS-sponsored fellowship
program, which offers training
in all aspects of ophthalmic
plastic and reconstructive surgery. As one of just 28 such
fellowships (only seven west of
the Mississippi), it has been
extremely competitive nationwide. Recently, CEI matched
its first choice yet again for the
fellowship beginning in July
2003.
17
John Ng, M.D. and Nancy Campbell, P.A.-C.
John D. Ng, M.D., covers the
hypoplastic eye socket disorder.
In addition to his clinical inno-
trauma, reconstructive and
He was the first in the country
vations, Ng plays an active role
pediatric portions of CEI’s
to implant these devices
in academic medicine. He is
Division of Ophthalmic Facial
(which were developed in
associate preceptor for
Plastic Surgery. Because
Germany and only recently
Casey’s ASOPRS fellowship,
Casey Eye Institute is the
FDA-approved), bilaterally and
helping train the next genera-
Pacific Northwest’s eye trauma
simultaneously. For Graves dis-
tion of oculoplastics specialists.
center, he serves patients from
ease, Ng does small incision
He is also co-editor and co-
Oregon, Washington, Idaho
orbital decompression, using a
author of the textbook
and northern California. Ng is
1-cm lateral canthal skin inci-
Evaluation and Treatment
currently developing new
sion (orbit only). Finally, he is
o f Orbital Fractures: A
orbital implants using Medpor
developing new approaches to
Multidisciplinary Approach,
Bioglass, a porous polyethyl-
orbital reconstruction using 3-D
to be published by
ene/silicone blend that has
stereolithographic technology
W.B. Saunders.
been shown to promote blood
to build custom orbital
vessel growth. By stimulating
implants. Using a 3-D model
growth, this new material can
based on CT imaging of a
decrease the time necessary to
patient’s head, Ng can shape a
complete vascularization by
custom implant from putty that
one-third to one-half. Ng also
is then built by the company.
uses Bioglass to repair orbital
Among his research interests,
implants.
Ng is exploring ways to
improve local anesthetic
In pediatric surgery, Ng is
refining his technique for
implantation of a new, selfexpanding orbital and socket
implant, used to treat congenital
administration in office-based
oculoplastic surgery and refining techniques to address ocular
problems in patients with facial
nerve paralysis.
18
PEDIATRICS - ELKS CHILDREN’S EYE CLINIC
Since Casey opened its doors, the number of children seen has
doubled and the volume of research has tripled.
The Oregon State Elks
patients, working on projects
have been integral in the success
for staff, and providing informa-
of the Elks Children’s Eye
tion to the public with a smile.
Clinic. This special relationship
The Elks also funded up-to-date
between the Department of
equipment for the pediatric
Ophthalmology and the Elks
ophthalmology exam room at
dates back to 1949, when
OHSU’s Doernbecher Children’s
Dr. Kenneth Swan needed an
Hospital, which is staffed by
oximeter for a baby whose
the faculty of the Elks Children’s
father was an Oregon Elk.
Eye Clinic.
The Elks raised $2000 for the
oximeter, and soon after, their
From the beginning, it was the
continued generosity estab-
Elks’ critical philanthropic
lished our pediatric clinic.
support that allowed Casey’s
founder Kenneth C. Swan, M.D.,
In the years since, the Elks
to recruit top faculty. “They’ve
have contributed enormously
given us an edge,” notes Earl
to eye care at OHSU. They
Palmer, M.D., head of the Elks
helped pay for the nation’s first
Children’s Eye Clinic. Our
microscope for ocular surgery,
pediatrics service has also
the Northwest’s first ophthalmic
been blessed with significant,
excimer laser, and Oregon’s
ongoing support from the
first photokeratoscope for
Annie E. Casey Foundation,
children. Today, the Oregon
which has allowed us to
State Elks Association con-
expand our services.
tributes over $500,000 per
year to the Elks Children’s Eye
For more than 50 years, the
Clinic and the Oregon School
Elks Children’s Eye Clinic has
for the Blind.
conducted cutting-edge eye
research and provided superior
Oregon Elks donate thousands
eye care for children in the
of hours volunteering at the
Pacific Northwest. Dr. Palmer is
Casey Eye Institute—assisting
principal investigator and chair
19
David T. Wheeler, M.D.
Earl A. Palmer, M.D.
of the NIH-sponsored, multi-
safety monitoring committee for
Since Casey Eye Institute
center trial “Cryotherapy for
a multicenter consortium, the
opened its doors in 1991, the
Retinopathy of Prematurity”(ROP).
Pediatric Eye Diseases
number of pediatric patients
Begun in 1986, this nationwide,
Investigative Group (PEDIG).
seen here has doubled, and
landmark study was designed
Wheeler is an investigator for
the volume of research has
to help physicians determine
this group, working on the now
tripled. As a major Pacific
when and how to treat ROP in
complete Congenital Esotropia
Northwest referral center, the
order to save as many chil-
Observational Study as well as
Elks Children’s Eye Clinic treats
dren’s vision as possible. The
on several amblyopia studies.
approximately 8,000 children
study’s results have revolution-
He is also an investigator in the
each year. The four current
ized ROP management and
Infant Aphakia Treatment Study
faculty- Palmer, Laurie
inspired more research.
(IATS), researching the best
Christensen, M.D., Stout, and
way to care for infants younger
Wheeler- plan to add one more
Today Dr. Palmer serves on the
than 6 months who develop a
member to the department
executive committee for a
cataract in one eye. He partici-
through a pediatric
multicenter trial that will help
pates in OHSU’s Human
fellowship program that will
identify infants at high risk for
Investigations Program, one of
begin in the near future.
ROP earlier than in the past.
only five such programs in the
David T. Wheeler, M.D., is
country designed by the NIH to
Oregon’s principal investigator
stimulate physician leadership
and Ann U. Stout, M.D., is a
in clinical research.
co-investigator in this “early
treatments” study, while
researcher Michael Powers,
M.D., is studying retinal vessel
development in a parallel effort
to better understand ROP.
Our pediatrics faculty participate in several other clinical
trials, all federally funded by
the National Eye Institute.
Palmer belongs to the data and
20
NEURO-OPHTHALMOLOGY
Our team sees patients with the entire spectrum of
neuro-ophthalmic disorders.
Robert Egan, M.D., and
blood vessel behind the
W. Thomas Shults, M.D.,
patient’s eye, and clot-
form a critical team of clini-
busting medication is used
cian investigators who see
to dissolve clots that have
patients with the entire
blocked the blood supply
spectrum of neuro-
to the retina.
ophthalmic disorders.
These include ischemic
As in the other subspecialties
optic neuropathy, optic
at the Casey Eye Institute,
neuritis, optic atrophy,
the neuro-ophthalmology
stroke, multiple sclerosis,
unit actively participates in
cranial nerve palsies, brain
several research projects.
tumor, myasthenia gravis,
Subjects diagnosed with
thyroid eye diseases, psy-
Leber’s hereditary optic
chiatric disorders and
neuropathy in one eye are
unexplained visual com-
being studied to determine
plaints.
if treatment with an eye
drop medication will
Robert Egan, M.D.
Through a dynamic collab-
decrease their risk of
oration between the neuro-
developing this condition in
ophthalmology service, the
the other eye.
Oregon Stroke Center, and
the Dotter Interventional
The relationship between
Institute in the OHSU
neuro-ophthalmologic
School of Medicine,
signs and stroke is also
patients are being evaluated
being investigated, as is
and treated for acute reti-
the link between optic
nal artery occlusion. A
nerve hypoplasia and
catheter is inserted into a
epilepsy.
21
CASEY OPHTHALMIC ASSOCIATES
Physicians Bring Diverse Backgrounds to Patient Care
Casey Ophthalmic Associates
ophthalmologists working in con-
cares for a wide-ranging popula-
junction with the American Academy
tion as the general ophthalmology
of Ophthalmology on the Systematized
service at the Casey Eye Institute.
Nomenclature of Medical Reference
The staff includes Kelly Chung,
Terminology (SNOMED) project.
M.D., William Farr, M.D., and Devin
This collaborative endeavor
Gattey, M.D., who recently joined
between the United Kingdom and
the group to accommodate grow-
the United States is producing a
ing numbers of patients. Tammie
comprehensive medical terminolo-
Krisciunas, O.D., specializes in
gy database to be used worldwide
contact lens care. With the assis-
as the basis for all medical software.
Devin Gattey, M.D., recently joined
tance of the OHSU Translation &
As Chung states, “This terminology
Casey Ophthalmic Associates.
Interpreter Services, care is provid-
is much different than say, ICD or
Having served in the Peace Corps
ed to patients speaking some 40
CPT, because it is modeled using
in Nepal, his interests gravitate
different languages.
artificial intelligence, so information
toward international medicine.
searches are very robust. For
During his inaugural medical mis-
instance, a search for all patients
sion, he accompanied a team to
with open angle glaucoma would
Peru, performing cataract
retrieve not only patients with
surgery on native Indians living at
“POAG,” but also pigmentary glau-
an elevation of over 14,000 feet. In
coma, low tension glaucoma and
May of this year, Gattey will journey
pseudo-exfoliation glaucoma with-
to Guatemala as part of another
out the user specifying or knowing
medical team. “My long term goal is
that these conditions are types of
to establish an international clinic
open angle glaucomas. That knowl-
where Casey providers can have
edge is built into the system.” Also,
this kind of experience. Despite
since SNOMED has been translat-
the monumental task of putting a
Chung blends a busy clinical and
ed into several languages, it will
team together, it is a life-changing
surgical practice with her interest
truly give physicians a common
experience.”
in medical informatics, the science
medical language.
Kelly Chung, M.D.
of developing and using information technologies to improve health
care. Nationally, she is one of two
Devin Gattey, M.D.
22
CLINICAL TRIALS and STUDIES
CORNEA
NE-91: Hyperopia and Hyperopic Astigmatism (H-LASIK) with the
Nidek EC-5000 Excimer Laser System
Principal Investigator: Larry Rich, M.D.
Sponsor: Nidek
Purpose: To compare the safety and predictability of PhotoRefractive Keratectomy (PRK),
PhotoAstigmatic Refractive Keratectomy (PARK), Laser in Situ Keratomileusis (LASIK), and
Astigmatic Laser in Situ Keratomileusis (A-LASIK) excimer laser methods in reducing
nearsightedness and nearsightedness with astigmatism.
Clinical
trials
are used to
determine
whether new
drugs or
treatments
are safe and
effective.
The following
studies are
currently
underway at
the Casey
and Devers
Eye Institutes.
Excision and Cryotherapy for Pterygia
Principal Investigator: Rick Fraunfelder, M.D.
Purpose: To study the recurrence rate of pterygia treated with excision and cryotherapy.
GLAUCOMA
Clinical Study to Evaluate the Effectiveness and Safety of Oral
Memantine in Patients with Chronic Open-Angle Glaucoma
Principal Investigator: John Samples, M.D. (Casey Eye Institute)
Sponsor: Allergan
Principal Investigator: Steven Mansberger, M.D., M.P.H. (Devers Eye Institute)
Purpose: To investigate the safety and efficacy of memantine supplied in tablets for the treatment of certain types of open angle glaucoma. The study drug has been sold in Europe for
treatment of dementia syndrome and spastic disorders, such as Parkinson’s disease, and is not
yet marketed in any country for use in glaucoma.
Chronology of Functional Deficits
Principal Investigator: Brad Fortune, O.D., Ph.D.
Sponsor: Legacy Research Advisory Council
Purpose: This study considers the hypothesis that a generalized retinal neurodegeneration
involving glial cells and metabolic dysfunction exists in glaucoma.
Memantine Visual Field Reading Center
Principal Investigators: G.A. Cioffi, M.D. and C.A. Johnson, Ph.D.
Sponsor: Allergan
Purpose: To receive, analyze and interpret visual field data collected from worldwide study sites
and perform statistical analysis of data transferred from such sites.
Anterior Chamber to Schlemn’s Canal Shunts in the Surgical
Treatment of Glaucoma
Principal Investigator: John R. Samples, M.D.
Sponsor: Glaukos Corporation
Purpose: A new device which shunts aqueous directly from the anterior chamber to Schlemm’s
canal is being studied and appears to have some promise in lowering intraocular pressure
without surgical complications.
23
Genetic Studies of Glaucoma Patients
Principal Investigators: Mary Wirtz, Ph.D.
Sponsor: National Eye Institute
Purpose: To study the genetics of families with five or more affected individuals with primary open angle glaucoma,
drusen of the optic nerve, congenital glaucoma, and selected other secondary glaucomas.
Aquaflow™ Collagen Glaucoma Drainage Device
Principal Investigator: John R. Samples, M.D.
Sponsor: Staar Surgical
Purpose: To assess the efficacy and safety of the Aquaflow™ Collagen Glaucoma Drainage Device compared to
existing surgical methods of draining fluid from inside the eye, such as trabeculectomy. The Aquaflow device is made
from collagen derived from pigs, and is designed to be inserted into the outer tissues of the eye (sclera).
Evaluation of Multifocal Electroretinogram (MERG) for Use in Glaucoma
Principal Investigators: Brad Fortune, O.D., Ph.D., G.A. Cioffi, M.D.
Sponsor: Murdock Trust
Purpose: To evaluate and optimize a new diagnostic procedure known as Multifocal Electroretinography (MERG).
MERG will be compared to standard diagnostic procedures as well as to other new, highly sensitive diagnostic instruments for detection of early vision damage caused by glaucoma.
Intraocular Hypertension: A Multi-Center, Open Label Study to Determine if AntiGlaucoma Eye Drop Medicines Prevent or Delay Onset of Glaucoma in Patients
with Intraocular Hypertension
Principal Investigator: George Cioffi, M.D.
Purpose: To determine whether lowering high eye pressure with eye drop medication prevents or delays glaucoma in
patients with increased eye pressure.
Short Wavelength Automated Perimetry in the OHTS Trial
Principal Investigator: C.A. Johnson, Ph.D.
Sponsor: National Eye Institute
Purpose: To determine the effects of intraocular pressure lowering treatment versus no treatment on SWAP deficits in
ocular hypertension patients.
OHTS Visual Field Reading Center
Principal Investigator: C.A. Johnson, Ph.D.
Sponsor: National Eye Institute
Purpose: To process visual field data for the OHTS trial
Objective Perimetry in Glaucoma: Objective Perimetry Evoked Response
Analysis (OPERA)
Principal Investigator: Brad Fortune, O.D., Ph.D.
Purpose: To evaluate a new visual screening device that may provide earlier detection and better monitoring of
glaucoma.
Perimetry and Psychophysics in Glaucoma
Principal Investigator: Chris A. Johnson, Ph.D.
Purpose: To evaluate several new test procedures that are believed to detect the earliest changes produced by
glaucoma.
24
CLINICAL TRIALS and STUDIES
MACULA and RETINA
Genetics of Age-Related Macular Degeneration
Principal Investigator: Michael Klein, M.D.
Sponsor: National Eye Institute
Purpose: To find the genes that cause age-related macular degeneration. Identifying these disease-causing genes will
lead us directly to the cause of the disease.
Nutrition and Age-Related Macular Degeneration
Principal Investigator: Michael Klein, M.D.
Sponsor: Casey Eye Institute/Clinical Nutrition, OHSU/Tufts University Center of Aging
Purpose: To find out if increasing amounts of foods containing carotenoids, lutein and zeaxanthin will increase the level
of pigment in the macula and protect against macular degenerative changes.
Evaluation of Intravitreal Injections of EYE 001 (Anti-VEGF Aptamer) in Patients
with Exudative Age-Related Macular Degeneration (AMD)
Principal Investigator: Michael Klein, M.D.
Sponsor: Eyetech Pharmaceuticals
Purpose: To establish the safety and efficacy of intravitreal injections of EYE001 given in 6 week intervals.
Evaluation of Anecortave Acetate versus Visudyne in Patients with Subfoveal
Exudative Age-Related Macular Degeneration (AMD)
Principal Investigator: Michael Klein, M.D.
Sponsor: Alcon
Purpose: To evaluate the safety and effectiveness of anecortave acetate in preventing the growth of blood vessels
under the retina in subjects with AMD as compared to treatment with PDT and Visudyne.
A Study of ADGVPEDF.11D in Neovascular Age-Related Macular
Degeneration (AMD)
Principal Investigators: Michael Klein, M.D. and Timothy Stout, M.D., Ph.D.
Sponsor: GenVec, Inc.
Purpose: To evaluate the safety and effectiveness of this gene therapy medication in slowing the growth of the blood
vessels or improving vision.
Submacular Surgery Trials (SST)
Principal Investigator: David Wilson, M.D.
Sponsor: National Eye Institute
Purpose: To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hemorrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idiopathic CNV stabilizes or improves vision more often than observation.
Complications of Age-Related Macular Degeneration (CAPT)
Principal Investigator: Michael Klein, M.D.
Sponsor: National Eye Institute
Purpose: To determine whether application of low-intensity laser treatment of eyes with drusen in the macula can
prevent later complications of age-related macular degeneration and thereby preserve visual function.
25
AREDS: Age-Related Eye Diseases Study
Principal Investigator: Michael Klein, M.D.
Sponsor: National Eye Institute
Purpose: To assess the clinical course, prognosis, and risk factors of age-related macular degeneration (AMD) and
cataract; to evaluate the effects of antioxidants and zinc on the progression of AMD and antioxidants on the
development and progression of lens opacities.
CAREDS: Carotenoids in Age-Related Eye Disease
Principal Investigator: Michael Klein, M.D.
Sponsor: NIH Kaiser Permanente Women’s Health Initiative
Purpose: To look at environmental factors (diet, dietary supplements, sunlight exposure, family history) and their role in
age-related eye disease.
Oculex Pharmaceutical Study of Macular Edema
Principal Investigator: David Wilson, M.D.
Sponsor: Oculex Pharmaceuticals
Purpose: To determine the efficacy of a new dexamethasone implant delivery system in the treatment of persistent
macular edema associated with diabetic retinopathy, uveitis, retinal vein occlusion or Irvine Gass syndrome. This clinical research study evaluates the safety and effectiveness of an investigational medication to treat macular edema that
persists despite current treatment methods.
Optical Coherence Tomography in Diabetic Macular Edema
Principal Investigator: Robert Watzke, M.D.
Purpose: To determine the value of optical coherence tomography (OCT) in the clinical assessment of diabetic macular edema.
Clinical, Electrophysiological, and Molecular Evaluation of Retinitis Pigmentosa
and Allied Disorders
Principal Investigator: Richard Weleber, M.D.
Sponsor: Foundation Fighting Blindness
Purpose: To evaluate patients with retinitis pigmentosa and allied disorders, provide genetic counseling, and perform
DNA candidate gene screening to search for a molecular basis for these diseases.
Multifocal Electroretinographic Values of the Normal Eye
Principal Investigator: Robert Watzke, M.D.
Purpose: To perform multifocal electroretinographic testing on human eyes to test the electrical response of groups of
retinal nerve cells in the posterior pole. This is a new method of testing, and this study proposes to establish a standard of normal values in patients with normal eyes, older patients, and those with refractive errors.
Long-Term Sequellae in Parafoveal Telangiectasia
Principal Investigator: Robert Watzke, M.D.
Purpose: Parafoveal telangiectasia (PFT) is an ocular vascular disease characterized by abnormal retinal vessels. The
purpose of this study is to determine the long-term results of untreated PFT and its effect on vision. A secondary goal
is to determine whether it is associated with existing systemic disease, particularly diabetes.
26
CLINICAL TRIALS and STUDIES
NEURO-OPHTHALMOLOGY
Multi-Center Study of the Safety and Efficacy of Brimonidine-Purite 0.15%
Ophthalmic Solution Administered to Patients with Leber’s Hereditary Optic
Neuropathy
Principal Investigator: Robert Egan, M.D.
Sponsor: Allergan
Purpose: Leber’s hereditary optic neuropathy causes severe and permanent visual loss. To date, no effective treatment has been identified. This study hypothesizes that brimonidine purite 0.15% is effective in reducing visual acuity
loss.
Retinal Emboli in Acute Ischemic Stroke
Principal Investigator: Robert Egan, M.D.
Purpose: To determine the significance of emboli in the eyes to help determine the cause of the stroke.
Optic Nerve Hypoplasia and Epilepsy
Principal Investigator: Robert Egan, M.D.
Purpose: To determine whether patients with seizures or epilepsy have an increased incidence of optic nerve hypoplasia.
ONCOLOGY
Collaborative Ocular Melanoma Study (COMS)
Principal Investigator: David Wilson, M.D.
Sponsor: National Eye Institute
Purpose: 1) To evaluate therapeutic interventions for patients who have choroidal melanoma, and to assess the potential life-preserving as well as sight-preserving role of radiation therapy. 2) To determine which of two standard treatments, removal of the eye or brachytherapy, is more likely to prolong survival of eligible patients with medium-sized
choroidal melanoma. 3) To determine whether preoperative radiation prolongs life for patients whose eyes with large
choroidal melanoma are enucleated.
Breast Cancer and Vision
Principal Investigator: Al Eisner, Ph.D.
Sponsor: Oregon Cancer Institute
Purpose: To assess how the drug, tamoxifen, affects the visual system. The protocol consists of experimental tests of
visual sensitivity plus conventional ophthalmologic assessment.
Decreased Tumor Recurrence after Excision and Cryotherapy for Suface
Eye Malignancies
Principal Investigator: Rick Fraunfelder, M.D.
Sponsor: Collins Medical Trust
Purpose: To perform excision and cryotherapy on surface eye tumors and analyze results of tumor recurrence, visual
morbidity, tumor metastasis, and patient mortality. This research will serve as a basis for future studies into treatment
and prognosis of surface eye tumors.
27
PEDIATRICS
Outcome Study of Cryotherapy and Retinopathy of Prematurity
Principal Investigator and National Chairman: Earl A. Palmer, M.D.
Sponsor: National Institutes of Health/National Eye Institute
Purpose: Originally launched in 1985 to determine the safety and efficacy of trans-scleral cryotherapy of the peripheral
retina in certain low-weight infants with retinopathy of prematurity (ROP) for reducing blindness from ROP. Outcome
study is to determine the long-term outcome for eyes that had severe (“threshold”) ROP, both with and without
cryotherapy.
Early Treatment for Retinopathy of Prematurity Study (ETROP)
Principal Investigator: David Wheeler, M.D.
Sponsor: National Eye Institute
Purpose: To test the hypothesis that earlier treatment in carefully selected cases will result in an overall better visual
outcome than treatment at the conventional CRYO-ROP threshold point in the disease. “Early” treatment means the eye
is treated before the disease becomes severe.
Follow-up Study of the Early Treatment of Retinopathy of Prematurity
Trial (ETROP)
Principal Investigator: David Wheeler, M.D.
Sponsor: National Eye Institute
Purpose: Because the vision in babies and young children changes significantly, it is believed that there may be longterm differences between the earlier treated eyes and the eyes treated after ROP became severe. This study will follow
the vision of the children who were in the original ETROP study up to age 6.
Infant Aphakia Treatment Study (IATS)
Principal Investigator: David Wheeler, M.D.
Sponsor:: Emory University
Purpose: This is a pilot study which explores intraocular lens implantation in infants with monocular cataracts. The
purpose of this project is to find out which treatment will result in better vision for babies who are born with a cataract in
one eye: babies who have the cataract removed to the vision of babies who have the cataract removed and have an
intraocular lens put in.
Amblyopia Treatment Studies (ATS)
Principal Investigator: David Wheeler, M.D.
Sponsor: National Eye Institute
Amblyopia Treatment Study 1
Purpose: To determine whether the success rate with drug treatment (atropine) of amblyopia is equivalent to the success rate with occlusion (patching) therapy; to develop more precise estimates of the success rates of amblyopia treatment; to identify factors that may be associated with successful treatment of amblyopia; and to collect data on the
course of treated amblyopia to provide more precise estimates of treatment effects than are now available
Amblyopia Treatment Study 2: An Evaluation of Patching Regimens for Amblyopia
Purpose: ATS 2 evaluates patching regimens for amblyopia. The treatment of choice for amblyopia is patching the
good eye. However, we do not know how many hours per day the patch should be worn for the best results.
Depending on the severity of the amblyopia, the patch will be worn either all day or for 6 hours per day.
28
CLINICAL TRIALS and STUDIES
PEDIATRICS (continued)
Amblyopia Treatment Study 3: Evaluation of Treatment of Amblyopia in
7 to < 18 yr olds
Purpose: ATS3 assesses the effectiveness of amblyopia treatment in 7 to <18 year olds. If amblyopia is treated by the
time a child is 6 years old, vision usually improves. In older children, we do not know how often improvement can
occur with treatment, and we do not know the best treatment to prescribe. This study explores whether treatment with
patching plus an activity to force the child to use his or her weak eye will improve the child’s vision.
Amblyopia Treatment Study 4: A Randomized Trial Comparing Daily Atropine
Versus Weekend Atropine for Moderate Amblyopia
Purpose: The primary objective of this study is to compare the visual acuity outcome in the amblyopic eye after 17
weeks of daily use of atropine versus weekend only use of atropine.
UVEITIS/INFLAMMATORY DISEASES
Genetics of Uveitis Study
Principal Investigator: Tammy Martin, Ph.D.
Sponsor: National Eye Institute
Purpose: To search for genes or genetic factors that contribute to the development of acute anterior uveitis (or iritis).
Many patients with uveitis have family members that also have uveitis. Our ultimate goal is to be able to treat or even
prevent uveitis by better understanding the genetics of this disease.
Use of Remicade in the Management of Vision-Threatening Uveitis
Principal Investigator: James Rosenbaum, M.D.
Sponsor: Centocor, Inc.
Purpose: To test the hypothesis that inhibition of binding between tumor necrosis factor alpha and its receptors using
infliximib (Remicade®) is clinically useful in patients with uveitis that is refractory to other forms of systemic immunosuppressive therapy. Infliximab is given by infusion every 2 months after a loading schedule. It is well tolerated. Recently,
the increased risk of infection has been publicized.
Intravitreal Fluocinolone Acetonide Implant in Patients with
Non Infectious Uveitis
Principal Investigator: James Rosenbaum, M.D.
Sponsor: Bausch & Lomb Pharmaceuticals
Purpose: To evaluate the safety and efficacy of intravitreal fluocinolone acetonde implants in the management of
patients with non infectious uveitis affecting the posterior segment of the eye. This study also compares the safety and
efficacy of 2 doses of fluocinolone acetonide delivered by an intraocular/intravitreal implant in patients with non infectious uveitis affecting the posterior segment of the eye. This trial involves implantation of a device which slowly releases
corticosteroid over a period of 3 years.
29
HONORS AND AWARDS
Elizabeth Cottle, C.P.C., Casey Eye Institute’s
Larry F. Rich, M.D., holds the August Petti and
coding and compliance officer, received the Pinnacle
Award (large practice division) from the American
Society of Ophthalmic Administrators, the administrative branch of the American Society of Cataract &
Refractive Surgeons (ASCRS). The award was presented at the ASCRS-ASOA meeting in June 2002.
Margaret Thiele Petti Chair for the Director of Corneal
Service. This chair was created in his honor.
Roger A. Dailey, M.D., holds the Lester T.
CEI director Joseph E. Robertson, M.D., M.B.A.,
holds the August Petti and Margaret Thiele Petti Chair
of Ophthalmology, created in honor of Kenneth C.
Swan, M.D. He received the 2002 Dean’s Award from
the OHSU School of Medicine.
Jones Chair in Ophthalmic Facial Plastic Surgery, the
only endowed chair in the country in this subspecialty.
James T. Rosenbaum, M.D., holds the
Frederick T. “Fritz” Fraunfelder, M.D.,
former CEI chair, was recently named to the Scientific
Advisory Panel of Research to Prevent Blindness. He
also received the International Society of Ocular
Toxicology’s Scientific Award at its 2002 meeting in
Lindau, Germany.
Edward E. Rosenbaum Chair in Inflammation Research.
Elected president of the American Uveitis Society, he
also received a Discovery Award from the Medical
Research Foundation and won a Faculty Excellence in
Education Award from the OHSU School of Medicine in
2002.
Justine Smith, M.D., Ph.D., received a
Rachael Garrett, O.D., was named Young
Optometrist of the Year for 2002 by the Oregon
Optometric Physicians Association. She was also president of the Portland Metropolitan Optometric Society in
2001-02.
William Mathers, M.D., was recently honored
with the Physician-Scientist Award from Research to
Prevent Blindness.
Career Development Award from Research to Prevent
Blindness.
J. Timothy Stout, M.D., Associate Professor
of Ophthalmology, is the recipient of a McCormick
Scholar Award from Research to Prevent Blindness. He
also won the Casey Eye Institute Resident Teaching
Award in 2002.
Richard G. Weleber, M.D., received a 1.5
John C. Morrison, M.D., won the Lew R.
Wasserman Merit Award for Glaucoma Research from
Research to Prevent Blindness.
John D. Ng, M.D., received an Achievement
Award from the American Academy of Ophthalmology.
million grant from the Foundation Fighting Blindness to
benefit the Oregon Retinal Degeneration Center. He is
vice president for the Americas of the International
Society for Clinical Electrophysiology. In 2002, he delivered the Franceschetti Lecture at the International
Society for Genetic Eye Disease (published in the
Journal of Ophthalmic Genetics).
Earl A. Palmer, M.D., was named to Who’s
Who in America for 1999-2002 and Who’s Who in the
West for 2001-02. He was listed as one of “America’s
Top Doctors” in 2001 and one of the “Best Doctors in
America” in 2002.
Mary Wirtz, Ph.D., discovered (with John
Samples, M.D.) the sites for two of the six known genes
for primary open-angle glaucoma, evaluating them
both in Portland and in Greece.
30
C L I N I C A L a n d R E S E A R C H F A C U LT Y
Cornea and External Disease
Frederick T. (Fritz) Fraunfelder, M.D.
Professor of Ophthalmology
Interests: Anterior segment disease, ocular cancer,
ocular pharmacology and toxicology.
Frederick W. (Rick) Fraunfelder, M.D.
Assistant Professor of Ophthalmology
Interests: Cornea and external disease, anterior
segment oncology, cataract and refractive surgery,
corneal transplantation, anterior segment reconstruction.
Rachael L. Garrett, O.D.
Instructor
Interests: Pre- and postoperative refractive surgery
evaluation.
Damien Macaluso, M.D.
Assistant Professor of Ophthalmology
Interests: Cornea and external disease, refractive
surgery, corneal transplantation, complicated cataract
and anterior segment surgery.
William D. Mathers, M.D.
Professor of Ophthalmology
Interests: Corneal transplantation, refractive surgery,
corneal diseases, tear film abnormalities, dry eye,
confocal microscopic detection of corneal infections.
Larry F. Rich, M.D.
Professor of Ophthalmology
Interests: Refractive surgery, corneal transplantation,
treatment of corneal diseases.
General Ophthalmology
Kelly D. Chung, M.D.
Assistant Professor of Ophthalmology
Interests: Cataract/IOL surgery, medical informatics,
education for primary care providers and residents.
William F. Farr, M.D.
Clinical Associate Professor of Ophthalmology
Interests: Comprehensive ophthalmology, aviation
medicine.
Devin M. Gattey, M.D.
Assistant Professor of Ophthalmology
Interests: Comprehensive and hospital-based
ophthalmology, cataract and IOL surgery, international
ophthalmology.
Tammie Krisciunas, O.D., M.Ed.
Instructor
Interests: Contact lenses.
Kenneth C. Swan, M.D.
Professor Emeritus of Ophthalmology
Interests: Comprehensive ophthalmology.
Glaucoma
Ted S. Acott, Ph.D.
Professor of Ophthalmology, Biochemistry &
Molecular Biology
Interests: Understanding the molecular causes of
primary open-angle glaucoma and the molecular
mechanism of laser trabeculoplasty.
Elaine C. Johnson, Ph.D.
Assistant Professor of Ophthalmology
Interests: Developing physiologically relevant human
glaucoma models. Discovering mechanisms of
glaucomatous neuropathy and testing potentially
neuroprotective therapies.
Mary Kelley, Ph.D.
Assistant Professor of Ophthalmology
Interests: Primary open angle glaucoma.
John C. Morrison, M.D.
Professor of Ophthalmology
Interests: Evaluation and treatment of difficult glaucomas, glaucoma and cataract surgery, understanding
the mechanism of glaucomatous optic nerve damage.
31
Low Vision
John R. Samples, M.D.
Professor of Ophthalmology
Interests: Glaucoma diagnosis and therapeutics,
pediatric glaucoma, use of anti-metabolites, setons
and combined cataract and glaucoma surgery. Cell
biology of the eye, particularly trabecular meshwork.
Facial movement disorders.
Mary K. Wirtz, Ph.D.
Associate Professor of Ophthalmology, Molecular and
Medical Genetics
Interests: Identifying genes involved in the pathogenesis of glaucoma.
Uveitis and Inflammatory
Diseases
Tammy Martin, Ph.D.
Research Assistant Professor of Ophthalmology
Interests: Analysis of genetic susceptibility to anterior
uveitis.
Stephen Planck, Ph.D.
Research Associate Professor of Ophthalmology, Cell &
Developmental Biology, and Medicine
Interests: Intercellular regulation of ocular inflammation
and injury responses.
James T. Rosenbaum, M.D.
Professor of Ophthalmology, Medicine and Cell Biology
Interests: Ocular inflammatory disease, uveitis, scleritis,
orbital pseudotumor, ocular cicatrical pemphigoid, systemic inflammatory diseases with ocular manifestations.
Justine R. Smith, M.B.B.S., Ph.D.
Assistant Professor of Ophthalmology
Interests: Mechanisms of uveitis and related diseases,
and the design and testing of therapies that specifically
inhibit these mechanisms.
Eric B. Suhler, M.D.
Assistant Professor of Ophthalmology
Interests: Uveitis and ocular inflammatory diseases,
evidence-based ophthalmology, and the eye in
systemic disease.
John M. Boyer, O.D.
Assistant Professor of Ophthalmology
Interests: Low vision, vision impairment, vision
rehabilitation.
Neuro-Ophthalmology
Robert A. Egan, M.D.
Assistant Professor of Ophthalmology and Neurology
Interests: Neuro-ophthalmology, stroke, ocular motor
disturbances, ischemic optic neuropathy, pseudotumor
cerebri, optic neuritis.
William T. Shults, M.D.
Clinical Professor of Ophthalmology and Neurology
Interests: Neuro-ophthalmology, optic neuritis, and
other optic nerve diseases.
Ophthalmic Plastic and
Reconstructive Surgery
Roger A. Dailey, M.D.
Associate Professor of Ophthalmology
Interests: Cosmetic and reconstructive surgery, lacrimal
surgery, endoscopic and laser surgery, orbital surgery.
John D. Ng, M.D.
Assistant Professor of Ophthalmology
Interests: Reconstructive eyelid surgery, lacrimal surgery, orbital and facial trauma, facial nerve palsy rehabilitation, orbital reconstruction.
Pediatric Ophthalmology and
Strabismus
(Elks Children’s Eye Clinic)
Laurie E. Christensen, M.D.
Assistant Professor of Ophthalmology and Pediatrics
Interests: Strabismus, diplopia and ocular motility disorders (children and adults), ocular torticollis, retinoblastoma, general pediatric vision care.
32
C L I N I C A L a n d R E S E A R C H F A C U LT Y
Pediatric Ophthalmology and
Strabismus
(Elks Children’s Eye Clinic)
continued
Earl A. Palmer, M.D., F.A.A.P.
Professor of Ophthalmology and Pediatrics
Interests: Strabismus, diplopia and ocular motility
disorders of adults and children. Ocular torticollis,
ocular sequelae of premature birth, general pediatric
vision evaluation and care.
Ann U. Stout, M.D.
Assistant Professor of Ophthalmology
Interests: Strabismus and ocular motility disorders of
adults and children, pediatric glaucoma, pediatric
cataracts, general pediatric vision evaluation and care.
David T. Wheeler, M.D.
Associate Professor of Ophthalmology
Interests: Pediatric cataract removal and lens implantation,
pediatric glaucoma, strabismus in children and adults,
pediatric ocular trauma, pediatric tearing, general
pediatric vision evaluation and care.
Retina and Vitreous Disease
Alvin Eisner, Ph.D.
Associate Professor of Ophthalmology and Behavioral
Neuroscience
Interests: Visual psychophysical techniques.
Michael L. Klein, M.D.
Professor of Ophthalmology
Interests: Macular degeneration, diabetic retinopathy,
macular and retinal vascular diseases.
Andreas Lauer, M.D.
Assistant Professor of Ophthalmology
Interests: Vitreoretinal disease and surgery, ocular
trauma and ocular trauma surgery, macular
degeneration.
Joseph E. Robertson, M.D., M.B.A.
Professor and Chair of Ophthalmology
Interests: Macular surgery, ultrasound, trauma,
retinopathy of prematurity, surgical diseases of the retina and vitreous.
Dennis W. Schultz, Ph.D.
Research Assistant Professor of Ophthalmology
Interests: Macular degeneration research.
J. Timothy Stout, M.D., Ph.D.
Associate Professor of Ophthalmology
Interests: Pediatric vitreoretinal disease and surgery,
ocular gene therapy, ocular trauma, macular surgery.
Robert C. Watzke, M.D.
Professor of Ophthalmology
Interests: Research and treatment of diseases of the
retina and vitreous.
David J. Wilson, M.D.
Professor of Ophthalmology
Interests: Ocular oncology, macular degeneration, ophthalmic pathology, retinal and vitreous surgery, ocular
trauma and ocular trauma surgery.
Retinal Dystrophies and
Ophthalmic Genetics
Richard G. Weleber, M.D.
Professor of Ophthalmology
Interests:Ophthalmic genetic disease, retinitis pigmentosa, retinal dystrophies and degenerations, syndromes
with retinal degeneration, juvenile or early adult-onset
macular dystrophies.
33
FELLOWS
Daryl Kurz, M.D.
Uveitis and ocular immunology
CASEY’S RESIDENCY PROGRAM
Affiliated with the Oregon Health & Science University School of
Medicine and directed by Andreas K. Lauer, M.D., the Casey Eye
Raghu C. Murthy, M.D.
Vitreoretinal disease and surgery
Stanley M. Saulny, M.D.
Ophthalmic plastic and reconstructive surgery
Institute’s residency program is one of the most sought-after in the
United States. In 2002 we received more than 300 applications for
four positions starting in July 2004.
One reason for this popularity may be CEI’s high faculty-to-resident
Jonathan Yoken, M.D.
Vitreoretinal disease and surgery
RESIDENTS
First-Year (2002-2005)
Dustin Heringer, M.D.
University of North Dakota, 2001
ratio, which affords residents the opportunity to observe many different practice styles and allows a healthy balance between supervision and graded responsibility. Casey’s proximity to Devers Eye
Institute and the Portland Veterans Administration Medical Center
(conveniently linked to OHSU Hospital by a skybridge), means
additional clinical and surgical experience for residents; our status
as a “top ten” national research center, with over $10 million per
Thuy Ha Nguygen, M.D.
Oregon Health & Science University, 2001
year in external funding, means an abundance of scientific opportunities. In fact, Casey residents have a dedicated research rotation
during their first year. Our curriculum also includes courses in prac-
Carrie A. Lucidi Phillipi, M.D.
University of California at Davis, 1999;
Ph.D., University of California at San Diego
(neurosciences)
tice management designed to help prepare residents for a future in
either academic medicine or private practice.
In our 120,000-square foot, state-of-the art facility, residents receive
Eric Alan Steele, M.D.
Baylor College of Medicine, 2001
excellent training in comprehensive ophthalmology and exposure to
all of the generally recognized ophthalmology subspecialties.
Second-Year (2001-2004)
Christopher Barone, M.D.
Albany Medical College, 1999
Sandy Lifan Chen, M.D.
University of California at Davis, 2000
Christen K. Richard, M.D.
University of North Dakota, 2000
Jonathan Solomon, M.D.
Temple University, 2000
Third-Year (2000-2003)
Jane Gilbert, M.D.
University of Arizona, 1999
Susan Bony, Residency Program Coordinator
Thomas D. Myers, M.D.
University of Utah, 1999
Andrew S. Westfall, M.D.
Oregon Health & Science University, 1999
34
C o n t r i b u t i o n s t o C a s e y Ey e In s t i t u t e i n 2 0 0 2
The faculty and staff of Casey Eye Institute thank the following individuals, foundations, corporations and groups that
made charitable contributions to OHSU Foundation in support of Casey in 2002. Gifts were made for both unrestricted
and restricted purposes. We are grateful for the many and generous gifts we receive, and for those who have included
Casey in their estate plans.
Names followed by an asterisk indicate deceased donors. We have endeavored to make this list as
accurate and complete as possible, but should you find an error, or wish to be listed differently, please let us know.
Anonymous (9)
Mr & Mrs Mark W Bailey
Mr & Mrs John L Blackwell
Thomas Burk Jr
Bernita Abel
Mr & Mrs Stephen M Bailey
David G Blake
Dorothea L Burke
Don E Abraham
Mr & Mrs Wesley K Bailey
Eileen R Blaser
Mr & Mrs Thomas C Burnard
Ellen Abraham
Lorraine H Bajus
Dorothy L Blattner
Ruth K Burns
Mr & Mrs Tom Accettura
Mr & Mrs Benjamin J Baker
Mr & Mrs Keith D Bleich
Robert E Bush
Alice Julia Adams Estate
Bud Baker
Margery W Bloomfield
Michael E Butry
Marian P Ahlberg
Joanne F Baldasar
Dr & Mrs Lewis E Blue
Mr & Mrs Donald M Cades
Virginia A Ahrens
Mr & Mrs Bradley C Barclay
Bluebird Properties
Cahn Family Trust
Sheldon W Ainslie
Mr & Mrs James E Barnard
Mr & Mrs William H Boatman
Mr & Mrs Marvin S Cahn
Alcon Foundation
Mr & Mrs Eldon H Barnes
Mr & Mrs Gordon E Bock
Dr & Mrs Douglas T Campbell
Sherry E Allen
Dr & Mrs Richard Barrar
Mr & Mrs John F Bohler
Mr & Mrs John A Campbell
Allergan
Corleen M Barrett
Mr & Mrs Carl E Bond
Mr & Mrs Raymond U Cappelli
Mr & Mrs Kermit S Alskog
Mary M Bartholomew
Annette R Boslar
Mr & Mrs Billy D Carder
Dorothy C Ambrose*
Ronald L Bartlett
Lawrence P Bouchard
Mr & Mrs Milton Carl
Thomas L Ambrose Jr
Mr & Mrs Benjamin F Barton
Anna Belle Bowen
Mr & Mrs Claude W Carlile
Bernice E Anderson*
Mr & Mrs Thomas W Bartosz
Sally B Bowerman
Douglas M Carney MD
Bonnie B Anderson
Richard D Bartsch
John M Boyer DO
Frank P Carraher
Mr & Mrs Elven V Anderson
Mr & Mrs Noble D Bashor
Jean Braden
Brent R Carreau
Mr & Mrs Douglas W Anderson
Marie C Bates
Mr & Mrs John M Bradley
John A & Helen M Cartales
Mr & Mrs Frederick J Anderson
Marlys Jean Bauer
Carol L Brashear
Mr & Mrs Gordon A Anderson
Betty J Bauman
Mr & Mrs Fred J Breidenbach
Mr & Mrs Rodney B Carter
James C Anderson
Mary L Bauman
Jerome B Brem MD
The Annie E Casey Foundation
Margaret A Anderson
Mr & Mrs Harold J Beal
Beth and Chris Brentlinger
Myrna A Casono MD
Richard D Anderson
Chester Becker
Brobeck Phleger & Harrison LLP
George H Caspar MD
Robert H Anderson
Erna G Beggs
Mr & Mrs Murlin J Brock
Mr & Mrs Ted W Cauthorn
Mr & Mrs William C Anderson
Mr & Mrs Barry H Belau
Patricia G Brodkorb
Susie M Cawley
Mr & Mrs Duane Andrews
Alma J Belenski
Ida M Brooks
Mr & Mrs Leonard L Cebula
Androsia International Trade
Mr & Mrs Matt Benedict
Mr & Mrs Bobb F Brown
Mr & Mrs William H Chaffee
Captain & Mrs Phillip E Appleton
Elizabeth A Bennett
Christopher H Brown
Alan L Chaimov MD
Mr & Mrs Will B Arndt
Paul H Benninghoff
Gordon E Brown
Mr & Mrs Vutha Chau
Charles A Arnold
Mr & Mrs Elmo S Benton
Jean E Brown
Alyce R Cheatham
Bula Buck Arveson Estate
Mr & Mrs Donald I Berkey
Mr & Mrs John H Brunke
Mr & Mrs J M Checkoway
Mr & Mrs John C Ashton
Mr & Mrs George Bernards
Elia J Buckles
Mr & Mrs John D Chenoweth
Jean L Aslakson
Henny Bernstein
Janice I Budworth
Evelyn Christensen
Mr & Mrs Ray B Auel
Harry L & Renata Berry
Mr & Mrs L L Budzak
Laurie E Christensen MD
The Autzen Foundation
Mr & Mrs Mark S Bessette
William E Burch
Kelly D Chung MD
Aventis Pharmaceuticals Inc
Leslie Bevan PhD
Ella Munro Burdin Fund at
Mr & Mrs Michael Clarenbach
Mr & Mrs Edmund J Aziz
Claire E Beyer
Oregon Community Foundation
Clarendon National Insurance
Eleanore P Baccellieri
Mr & Mrs Everett E Bieger Jr
Elizabeth A Burgess
Annette Backous
Mary & Brot Bishop
Mr & Mrs Robert C Burgess
Clark Foundation
Mr & Mrs Victor Backstrom
John R Bjoin
Mr & Mrs Kenneth E Burgus
George L Clark
Mr & Mrs Warren R Bacon
Mr & Mrs Norman E Bjorklund
Gretchen A Burk
James B Clark
Nadia R Badawi
Mr & Mrs Jack L Bjorkman
Mr & Mrs Randal T Burk
Mr & Mrs Jerry J Clark
Foundation
Company
35
Leona M Clark
Charles J Custer
Mr & Mrs Craig R Duvall
Mr & Mrs Brian D Fitzgerald
Mrs Mary Clark
Mr & Mrs W G Custer
Joanne L Earle
Helen D Fitzgerald
Maurie D Clark*
Ellen B Dagan
Emma Early
John D Flanagan MD
Mr & Mrs Mike Clark
Raymond H Dahl
Colonel & Mrs Frank Easley
Mrs Doris M Floura
Mr & Mrs W Lewis Clark
Mr & Mrs A Dennis Dahlin
Marilyn S Easly
Helen C Fong
Nancy L Clary
Betsy W Dailey
Martha Eaton
Eunice G Forinash
Mr & Mrs Patrick J Clary
Roger A Dailey MD
Ronald G Ebel MD
Hazel Forty
Mr & Mrs Judson B Clifton
Barbara Dalman
Jill Edelson
Mr & Mrs Walter W Foster
Darin B Closson OD
Maude Daniels
Richard H Edelson MD
The Foundation for Fighting
Mr & Mrs Donald A Cobert
Stanley E Danill
Lynnell Edwards
Dr & Mrs William Cohen
Patricia A Darby
Pleasant L Edwards
Carolyn Fowler
Hilda Cohrs
Beatrice Darlington
Mr & Mrs Edward C Egan
Geoffrey G Fowler
Jesse L Colbert
Evan T Davies
Robert A Egan MD
Cluff E Francis*
Mr & Mrs Albert D Cole
Mr & Mrs N D Davis
Mr & Mrs Merle T Egge
Irene M Francis
Ethel L Cole
Mr & Mrs James E Davis
Lester H Eisendorf MD
Dr & Mrs Frederick T Fraunfelder
Doris H Coles
Mr & Mrs Mark D Davis
Sylvia Eisendorf
Rick Fraunfelder MD
Vicki L Coles
Marvel D Davis
Robert M Eisinger
Percy F Freeman Jr
Collins Medical Trust
Mr & Mrs Ralph M Davis
Mr & Mrs Jerry L Ekstrom
Mr & Mrs George J Freiberg
D J Collins
Mary A De Witt Smith MD
Janice G Elder
Don & Emilie Frisbee
Judy M Collins
Beverly DeAngelo
Mr & Mrs Harrison W Elgin Jr
Shirley P Frisz
Maribeth W Collins
George R Dederyan
Mr & Mrs James H Elgin
Mr & Mrs John N Fullenwider
Gerald V Colombo
Robert DeGallery
Mr & Mrs Robert C Elgin
Mr & Mrs Oliver H Funk Jr
Joyce F Colwell
Richard & Mary Deich
Robert Eliason
Lloyd M Gabriel
Community Bargain Counter
Dr & Mrs James Rodney Delp
Elk-On-Wheels Travel Club
Wayne L Gannon
Community Health Charities
Mr & Mrs Thomas P Delsman
Mr & Mrs Harold C Ellicott
Gap Foundation Gap Giving
Mr & Mrs Randy Compton
Ruth M Demers
Sachiko T Ellis
Consolidated Auto Works
Hattie A Dennis
Ellis-Ranian Travel Inc
Mr & Mrs Burton S Garbow
Mr & Mrs John A Conway
Janet L Dennis
H C Enloe
Melvin C Garbow
William V Cook
Mr & Mrs John E Depweg
Mr & Mrs Thomas M Ensman
Mr & Mrs Pat E Garcia
Mr & Mrs William N Cooper
Elizabeth Descamps
Jean Epstein
Rachael L Garrett OD
Albert S Copeland
Desert Camera Club
Mr & Mrs George E Erickson
Goldie Gaska
Ruth Copenhagen
Desert Grove Mobile Estates
Raymond L Erickson MD
Mr & Mrs J Peter Gaskins
Barbara J Cordill
David Dethlefsen
Mr & Mrs Charles W Ertelt
Mr & Mrs Daniel K Gassner
Wade W Cornwell
Donald Dickey
Elizabeth C Evans
Devin M Gattey MD
Lionel Correia
Marjorie Dickman
Mark S Evans
Marcile M Gatzke
Elizabeth D Cottle
William C Dietz DMD
Sandra L Evans
Janet Gefre
Mr & Mrs John A Courtney
E Jean Dillard
ExxonMobil Foundation
Mr & Mrs Charles T Geldaker
Mr & Mrs Donald G Cowgill
Gail W Dils
Mr & Mrs Stanley E Farr
Carolyn S Gentry
Mr & Mrs William F Cowning
Tuan Anh Do
William F Farr MD
Mr & Mrs Theodore Gerson
Janice Cramer
Rachel Dohanian
Jennifer Farrer
Mr & Mrs Richard J Gibler
Loy E Cramer MD
Viola A Donahue
Ruth A Fasbinder
William J Gibler
Jennie M Crane
John Dooley
John N Fax
Evelyn E Gieszler
William C Crane
Mr & Mrs Donald D Doran
Ruby E Fax*
Mr & Mrs Dale Gilkison
Janet L Crawford
Mr & Mrs Benjamin Dortch
Mr & Mrs George Ferrington
Mr & Mrs R A Girton
Crestwood Construction
DPR Construction
Myra L Ferris
Shirley Gittelsohn
Edward L Crockett
Aileen M Duckwall
Mr & Mrs Michael A Fiasca
Mr & Mrs Vernon D Gleaves
Edith B Cross
Mr & Mrs Maurice L Dufault
Dolores Fielder
Antonio J Glokner
Rosemary Crowder
Mr & Mrs Dominic A Dulcich
Allen Figone
Arlene W Glueck
Bernice Crump
Dr & Mrs David G Duncan
William S Findlay CLU ChFC
Helen Goffin
Mr & Mrs Carl L Cunningham
Mr & Mrs John H Dunkak
Mr & Mrs Roy E Finley
Mr & Mrs M M Goldhamer
Margaret M Curran
Donald A Durand
Rose M Finn
Norma J Goldsby
Current/Paper Direct
Fern Durbin
Debbie H Fisher
Mr & Mrs Jay Goldstein
Irja V Curtis
Fred W Durbin
Mr & Mrs James W Fisher
George & Carolyn Goodall
Helen F Cushing
Mr & Mrs Clark Duvall
Fishhawk Fisheries Inc
Blindness
Program
Foundation
36
C o n t r i b u t i o n s t o C a s e y Ey e In s t i t u t e i n 2 0 0 2
Mr & Mrs Robert L Goodman
Marilyn A Hart
Jo Ann Jacobsen
John B Kiefer
Shawn Goodman MD
Davis A Harvey Estate
Robert P Jacobsen Jr
Heather K Killough
Mr & Mrs Tom Gordon
Mr & Mrs Kirby B Haskell
Thelma M Jacobsen
Mr & Mrs Robert L Kimmel
Sarah L Gore
Milton Hasson DMD
Benjamin G Jacobson
Mr & Mrs Eugene C Kinder
LaVerda J Goudge
Dorothy I Hay
John Jaksic
Mr & Mrs Allen R King
Dr & Mrs Jack A Gow
Mr & Mrs Gary M Haynes
Mr & Mrs George James
Mr & Mrs Keith R Kingsley
Ruth A Grady
Mr & Mrs Harry E Hearn
Mr & Mrs Don G Jefferys
Barbara Kirkhart
Mr & Mrs Leal W Graham
Mr & Mrs Dan Heimbuck
Kelley S Jensen
Audrey & Joe Kirshenbaum
Mr & Mrs Thomas M Graham
Mr & Mrs Joseph L Heinz
Val & Mary Ellen Jensen
Donor-Advised Fund
Mr & Mrs Elden R Gray
Mr & Mrs Eugene H Helgerson
Bonnie R Jepsen
Stephen M Kiser
Victor R Greb
Marion Hembling
Irene Jessen
Mr & Mrs Kenneth S Klarquist
Mr & Mrs Lester D Green
Alexander Henderson Insurance
Mr & Mrs Henry N Jinings
Michael L Klein MD
Mr & Mrs Ronald W Griffin
V Carol Johns
Mr & Mrs Robert Klein
Eileen A Grigsby
Mr & Mrs Roger B Henderson
Services
Mr & Mrs Dale E Johnson
Fran Knapp
Mr & Mrs Howard A Grimes
Margaret M Hendricks
David S Johnson
Pamela K Kniffin
Mr & Mrs Cal R Grimmer
Emma B Henell
Gloria A Johnson
Karen Knippling
Mr & Mrs Robert S Grove
Margaret W Henzi
Mr & Mrs Marvin L Johnson
Robert Knockaert Jr
Stanley Gruszka
Josephine V Herman
Roger J Johnson
Edith E Knouff
Maruth G Gruver
Mr & Mrs Bertram J Hermens
Mr & Mrs Stanley B Johnson
Harley Koch
Mr & Mrs Anthony J Gubanc
Kathryn A Hibbard
Mr & Mrs Weston W Johnson
Karen G Koch
Gerry R Guest
Mr & Mrs Jim Hibbert
Jack F Johnston Jr
Richard W Kohl
Sandra G Guilfoil
Mr & Mrs Howard R Hickam
Evelyn L Jones Estate
Mr & Mrs August Kollom
GVNW Consulting Inc
Richard A Hiersche
Edeltrude Jones
Mr & Mrs William C Kolzow
Mardell M Gwinn
Dorothy Hiley
Dr & Mrs Richard T Jones
Mr & Mrs Joseph E Kordic
Bette B Hagman
Erland V Hill
Mr & Mrs Michael R Jordan
Kay E Kowitt
Stephanie A Hahn
Mr & Mrs Jeffrey A Hill
Harry S Joseph
Mr & Mrs Sanford Kowitt
Mr & Mrs Brian S Hair
Frederick A Hirsch
Mr & Mrs Thomas R Joste
Lloyd B Kozera*
Mary A Haisch
Mr & Mrs Harry K Hoard
Frances W Jubitz
Mr & Mrs Herman E Kraft
Guinivere B Hall
Mr & Mrs Philip M Hoefer
Marcia Kahn MD & Howard S
Mr & Mrs Calvin Krahmer
Mr & Mrs Kirby Hall
Mr & Mrs Charles Hoehner
Charlotte Hallowell
Michael G Holmes
Kaiser Permanente
Mr & Mrs Gary F Krahmer
Mr & Mrs Raymond W Haman
Margaret W Honeyman
Mr & Mrs Calvin L Kaser
Mr & Mrs Steven W Krake
Mr & Mrs Timothy Hamilton
Mr & Mrs Andrew J Honzel
Mr & Mrs Richard Kathrens
Claudine Kratzberg
Mr & Mrs Michael Hammack
Hooper Holmes
Ethel K Katz
Mr & Mrs Fred N Krecklow
Mr & Mrs J C Hammond
J A Houghton
Margaret Kearney
Tammie Krisciunas OD
Mr & Mrs Robert H Hango
Mr & Mrs Raymond M Hovee
Lewis G Kearns
Mr & Mrs Keith Kruchek
Michael C Hankins
Mr & Mrs Robert W Howe
Mr & Mrs George E Keep
Mr & Mrs Kenneth R Kruger
Joseph J Hanna Jr
Mr & Mrs Howard L Hubbard
Keller Foundation
Susan Kuckenberg
Arthur Hansen
Harry E Hudson*
Esther G Kelley
Hilda Kullberg
Betty Q Hansen
Mary S Hudson
Mr & Mrs Cyrus H Kelly
Robert W Kullberg MD*
Jean C Hansen
Mr & Mrs Michael B Huffman
Fern A Kelly
Mr & Mrs Vincent E Kurpan
Mr & Mrs Donald O Hanson
Mr & Mrs Dave Huffstutter
Mr & Mrs Robert V Kelly
Mr & Mrs Howard D Kyle
Lumier E Hanzel MD
Louise Hults
Tamara L Kelly
RoJene LaBarbera
Mr & Mrs Cleo A Harding
Mr & Mrs Kenneth C Hume
Judith L Kennedy
Lachenmeier Enloe & Rall
Mr & Mrs James A Harper
Robert L Hurst
Louis J Kennedy
Dorothy E Lakaff
Sherris Harrell
Muriel Hyman
Grace Kent
Edward P LaKaff*
Bertha L Harris
Mr & Mrs John R Hyslop
Mr & Mrs Oscar F Kern
Mr & Mrs Richard E Lakeman
Diane Harris
The IFC Foundation
Mr & Mrs Donald E Kernutt
Mr & Mrs Ronald E Lambert
Mr & Mrs Wayne O Harris
Edgar F Imle
Samuel R Kerr
Anthony Landriscina
C Allan Hart Estate
Mr & Mrs John J Inskeep
Mr & Mrs Charles L Kibby
Mr & Mrs Donald H Landwehr
Rosenbaum MD
Donald L Krahmer Sr
37
Frank V Langfitt III
Helen G Marks
Virginia A Millerup
Enid Newman
Frank V Langfitt Jr
Mr & Mrs Dale J Marshall
Eugene C Mintkeski
Sandra W Newton
Violet L Langfitt*
Arleen A Martin
Paul S Minty
John D Ng MD
Cynthia A Larsen
Robert A Martin
Farhad Mirhady PhD
Mr & Mrs Jim Nicolaisen
Mr & Mrs J Brad Larsen
Gwendolyn S Mason
Nancy L Mitchell
Mr & Mrs Verne A Nielsen
Mr & Mrs Len R Larson
Mr & Mrs Donald E Mast
Rose Mitchell
Mr & Mrs Carl A Nolte
Eileen M Lassiter
Phyllis Master-Cohen
Mr & Mrs Richard Miyahira
Mr & Mrs James E Norem
Andreas Lauer MD
William D Mathers MD
Patricia L Mobley
Sharon L Norene
Mr & Mrs E E Lavier Jr
Mr & Mrs Leslie E Matson Jr
Barbara Modey
Mr & Mrs W A North Jr
Mr & Mrs C Rex Layton
Phyllis J May
Mr & Mrs Zoltan Mokrai
Mary E Nousanen
Annie Leap
Mayfair School Sunshine Club
Mr & Mrs Gerald L Mongillo
Guy Nowels
Ruth C Lear
Mr & Mrs Elmer C Mays
Irvin W Monk
Mr & Mrs Robert H Noyes Jr
Robert O Lee Estate
Mr & Mrs C W McBride
Mr & Mrs Alexander S Moore
Nu Master Chapter # 440 Beta
Susan L Lehr
Mr & Mrs Blair D McCabe
Mr & Mrs Darmond L Moore
Sigma Phi
Mr & Mrs James H Leiper
Edmund B McCall
Jack L Moore
Susan D Nunn
David A Leith
Andrew J McCann PE
Mr & Mrs Jerome A Moore
NW Natural
Lematta Foundation
Mr & Mrs John S McCormac
Mr & Mrs Richard B Moore
Kathryn Nyberg
Herman Lenz
Ms Elizabeth T McCoy & Mrs
Mary W Moreland
Mr & Mrs Harold Nygaard
Mr & Mrs Noel A Lesley
Anne McCoy
Dolores D Morelli
Dolores Oaklief
Betty B Leuthold
Kay McCoy
Patrick Morgan
Mr & Mrs Homer E Oblander
Richard Lee Levy Estate
Mr & Mrs John M McCullen
Mr & Mrs V H Morgan
Mr & Mrs George Okita
Violet Lewis Living Trust
Mr & Mrs Marvin G McEldowney
Dorothy N Morrison
Fumiko Okubo
Anita J Lewis
James C McFarland
John C Morrison MD
Mr & Mrs Donald Oldemeyer
Max E Lewis
Mr & Mrs Robert L McFarlane
Lynne H Morrison MD
Mr & Mrs Michael Z Olds
Eleanor L Liefke
Mr & Mrs J R McGinnis Jr
Mr & Mrs Todd H Morrison
Mrs Virginia E Oliver
Judith C Lillestol
Mr & Mrs Paul E McGovney
Paula T Morrow
Helen N Olson
Joanne M Lilley
Mr & Mrs W S McGuire
Jean Morse
Oliver D Olson
Mr & Mrs Willis Lilliquist
Mr & Mrs George I McInroy
Christopher R Moser
Mr & Mrs William F O'Neil
Mr & Mrs Robert M Lindahl
Mr & Mrs Donald H McIntyre
Mr & Mrs Kenneth A Moss
Peter & Claire Opton Fund of the
Eva V Lindsay
Jessie E McKenzie
Mr & Mrs R S Moss
Mr & Mrs Robert D Lindsey
Mark McKinney
Patricia Mueller*
Joecile Orcutt
Mr & Mrs Edward S Lohr
Mr & Mrs Paul F McMahon
Robert L Mueller MD
OHSU Medical Group Inc
Mr & Mrs Howard W Long
Claudia Lacey McNeil
Evelyn V Mullin
Oregon State Elks Association -
Karen M Lotz
Mary C McNulty
Mr & Mrs David M Munro
Mr & Mrs A S Lough
Ferne C McPhee
Patra Murdock
Oregon State Elks Visual
Mr & Mrs E Russell Love
Susan I Means & Gene R
Francis S Murphy
Program
Mr & Mrs John W Murphy
Raymond O'Reilly
Mr & Mrs Richard S Love
Osborne
Oregon Community Foundation
Elks Youth Eye Services (EYES)
Marlene A Lowe
Gilbert Meigs
Mr & Mrs Tim R Murphy
Preston H Orem
Mr & Mrs Robert R Lowry
Mr & Mrs George H Meistrell
Helen E Murray
Mr & Mrs Laimons Osis
Mr & Mrs Fred Lukasavage
Mr & Mrs Frank A Mena Jr
Mr & Mrs Robert J Murray
Susan K David Oswald
Mr & Mrs Scott B Lukins
Merck & Company Inc
Mr & Mrs Louis Nadell
Mr & Mrs W Scott Overton
Mr & Mrs Christopher A Lulay
Merck Company Foundation
Bernard H Naftalin
Mr & Mrs Alphonse J Pacella
Kenneth A Lundeberg MD
Mr & Mrs Dotson T Merritt
Doris S Naudain
The Honorable Robert W
Lt Col & Mrs Stanley R Luther
Mr & Mrs Matthias H Mesdag
John T Naylor*
Mr & Mrs James J Lydon
Joann M Metcalf
John V Naylor
Evelyn J Page
Mr & Mrs Myron H Maas
Metropolitan Pediatrics LLC
Ruth T Naylor
Richard M Page DDS
Damien C Macaluso MD
Mr & Mrs James T Meyer
Diana L Nead
Earl A Palmer MD
Elizabeth A Macaulay
Mr & Mrs Donald G Meyers
Mr & Mrs Clyde W Needham
Ruth E Palumbo
Maybelle Clark Macdonald Fund
Mr & Mrs Stanley Michalek
Terrence P Neiman
Erna Pamer
Mr & Mrs Ian Mackenzie
Miix Insurance Company
Dorothy F Nelsen
Pamplin Foundation
Enid J Mackin
Delia E Miller
Mr & Mrs B T Nelson
Papé Family Foundation
Mr & Mrs Haakon T Magnussen
Mr & Mrs Richard G Miller
Ruth Nero
Mr & Mrs Santino Paperini
Jack Majors
Mr & Mrs Steven C Miller
Mr & Mrs Wilfred N Neth
Dr & Mrs Brent M Parker
Thalia Malone Estate
Vera Miller
Frank L Newell
Mr & Mrs W L Parker
Packwood
38
C o n t r i b u t i o n s t o C a s e y Ey e In s t i t u t e i n 2 0 0 2
Mr & Mrs Bob L Parnell
Nicholas L Rains
Joan G Rosenbaum
Mr & Mrs Gilbert L Schroff
Mr & Mrs A Donald Parr
Joan A Randall
Robert A Rosenbaum MD
Schwabe Williamson & Wyatt
Marilyn J Pate
Joan L Ratliff
Thomas J Rosenbaum MD
Agnes E Schwarzin Estate
Thomas G Paterson Sr
Margaret Rawlinson
Stanley & Madelle Rosenfeld
Mr & Mrs Willard C Schwenn
Mr & Mrs Rolland E Patterson
Robert P Ray
Fund of Oregon Jewish
Linda F Schwerdt
Karol Peck
Louvera H Raymond
Meadow Pederson
Mr & Mrs William Reade
Mr & Mrs Mark H Rosenthal
Yvonne Scroggins
Mr & Mrs Morton D Pelzner
Mr & Mrs William L Reagan
Brenda Lynn Ross Vision Fund of
Mr & Mrs Lee Seeger
Mr & Mrs William Pendarvis
Martin W Reeves
Kathleen E Percell
Mr & Mrs Douglas S Rehwoldt
Helen Ross
Kenneth W Self
Mr & Mrs Albert D Perpuse
Mr & Mrs John W Reiley
Thelma M Ross
Robert K Semans
Chuck Perrott
Richard G Reiten
Editha Rowell
Lt Col & Mrs Richard W Sexton
Vesna Persun
Allen Reiter
Peter P Rowell MD*
Dorothy A Shannon
Sally N Peters
Laura M Reith
Eileen C Royster
Sharkey Family Charitable
Mr & Mrs Douglas L Peterson
Gertrude F Rempfer
Trelba L Rubenser
Foundation
Margarett D Peterson
Mr & Mrs William T Rennie
Mr & Mrs Randall Rubenstein
Mr & Mrs John E Shaw Jr
Mr & Mrs Paul L Pettry
Research to Prevent Blindness
Ronald L Rubin
Dr & Mrs Russell D Shelden
Mr & Mrs Jack D Pfeifer
Yancey Reser
Muriel H Ruble Yandle
Mr & Mrs Robert W Shepard
Ruth C Phalen
Jean S Reynolds
Mr & Mrs Roy J Rucker
Thomas Sheppard
William H Phalen*
Margaret D Rhodes
Mr & Mrs Rollie Ruehlman
Mr & Mrs Charles H Sherwood
Mr & Mrs Robert W Philip
Larry F Rich MD
Mr & Mrs Alexander Runciman
Mr & Mrs Yoshiro Shintani
Margaret F Phillips
Michael E Richl
Geneva Runciman
Shook Hardy & Bacon LLP
Mr & Mrs Michael G Phillips
Mr & Mrs David Richlen
Rodney Russell
Mr & Mrs Robert O Shrum
Wallace W Phillips Jr
Robert & Marilyn Ridgley
Mr & Mrs Ronald A Russell
William T Shults MD
Shirley M Pickett
Charitable Gift
Ramona F Russum
Mr & Mrs Sam J Simich
Saalfeld Griggs Gorsuch
Mr & Mrs Forrest W Simmons
Mr & Mrs Donald C Pierce
Fund of FICGF
Community Foundation
Oregon Community Foundation
Mr & Mrs Wesley D Scott
Reha P Seekins
Mr & Mrs Charles T Pietrok
Hugh B Riley
Alexander & Emerick
Mr & Mrs Roy M Simmons
Austin M Pitcher
Mr & Mrs James F Rippey
Liwanag L & Abundio L Sadang
Edith Sitzer
Platt Electric Supply Inc
Mr & Mrs Donald J Rischard
Salem Cardiology Associates
Mr & Mrs Hans E Skacel
Sandy & Harvey Platt
Greg P Rivelli
Salem Hospital Medical Staff
Mr & Mrs Monroe Sliger
Mr & Mrs Wilson G Plummer
Mr & Mrs George D Rives
Jack J Saltzman
Smith Helms Mulliss & Moore
Barbara L Poitras
Mr & Mrs Irvine Robbins
Marjorie Saltzman
Barbara A Smith
Robert & Barbara Polachek
Mr & Mrs John E Roberts
John R Samples MD
Catherine A Smith PhD
Deborah T Pollack
Harold L Robertson
Lillian L Sanchietti
Cherida Collins Smith
Dorothy Pomeroy
Mr & Mrs Joseph E Robertson Sr
William M Sander
Edward S Smith
Leonard Popick
Joseph E Robertson Jr MD
Mrs Marie D Sanders
Frederic W Smith MD
Mr & Mrs Gerald Poplack
Mr & Mrs Wayne M Robertson
Mr & Mrs Robert C Sanders
Lear L Smith
Mr & Mrs Robert E Potter
Amy Joyce Robinson
Wilbert Sanders*
Mr & Mrs Lloyd S Smith
Doris M Prentice
Anne E Robinson
Mr & Mrs Fred G Sartwell
Rena C Snyder
Mr & Mrs John M Prince
Mr & Mrs Philip J Robinson
Donna J Sather
Helen J Sokol
Linda Prinsen
Hazel L Robitsch
Jeaneatta Sautter
Mr & Mrs Verne R Sowers
Richard Pryne
Susan G Roeger
Mr & Mrs James M Sayers
Charles J Spady
Mr & Mrs David L Prysock
J L Rogers
Scharf Properties Ltd
Gail M Sparks
Donald E Pullen
Joan F Rolling
Alberta G Schmidt
Mr & Mrs Joe M Sparks
Ernestine H Pullen*
Mr & Mrs Guy H Rooth
Janette L Schneider
Mr & Mrs Ronald M Speed
Lorraine & Bill Purnell
Mr & Mrs Sidney L Rosen
Mr & Mrs Robert S Schneider
Mr & Mrs Ken Speer
Roger Pye
Edward E Rosenbaum MD
Mr & Mrs Stanley W Schneider
M Evalyn Speidel
Mr & Mrs John F Pynes
Howard S Rosenbaum MD
Leonard Schnitzer DMD
Mr & Mrs Robert C Spielman
Mr & Mrs Bill F Racine
Dr James T Rosenbaum &
Lois Schnitzer
Shirley Spurgeon
Shirley M Schriner
Ivy T Stacy
Norma Ragsdale
Dr Sandra J Lewis
39
James S Stacy*
Mr & Mrs T H Thomas
Mr & Mrs Irvin H Walsh
Woodland Park Hospital Auxiliary
Mr & Mrs Abraham B Stanton
Fred P Thompson Jr
Henry Walters
Jane K Woodward
James Stanton
Reverend & Mrs James S
Laura D Wanser Foundation
M L Wooster
Edward R Ward
Harriet B Workman
Mona M Stearns Estate
Thompson
Mr & Mrs Walter Steinbrenner
Kathleen Thompson
John C Warden
Stephen B Workman
Susan Stephan
Mary E Thompson
Mr & Mrs Edward J Warmoth
Margaret J Worstell
Edward A Stephens Estate
Mr & Mrs Michael G Thorne
Mrs Bert M Warner
Donald L Wright
Andree H Stevens
Mr & Mrs Bill G Thornton
Mr & Mrs David Warner
Dorothy R Wright
Mary Hoyt Stevenson Foundation
Donald E Thorpe
Mr & Mrs Marion R Warner
Kathleen Wrightson
Anne V Stewart
Lucille E Thronson
Neil O Warner*
Mr & Mrs Fred D Wristen
Jenifer Stewart
Charlotte Thuemmel
Washington County Council
William W & Janet E Wyse
Loran L "Stub" Stewart
Bettymae Todrank
Mr & Mrs Dale W Stewart
Jacqueline V Tompkins
Mr & Mrs Glenn W Watkins
Irene A Yamada
Mr & Mrs Virgil A Stiger
Rena Tonkin
Robert Watzke MD
Mr & Mrs Dan Yates
Mr & Mrs David A Stockton
Mrs Moe M Tonkon Fund at
Esther G Wayne
Kenneth G Yee
Mr & Mrs Byron W Webb
Juan Young Fund at
Mr & Mrs Herbert G Stoenner
Oregon Community Foundation
on Aging
Dr & Mrs Kan Yagi
Betty Stone
Tooze Duden Creamer Frank &
Teresa M Webb
Mr & Mrs Richard L Stoner
Hutchison
Rosmary Wegert
Janet E Young
Myrtha Storm
Theodora M Topp
Mr & Mrs Irving B Weinstein
Mr & Mrs Roy A Young
J William Stortz
Mr & Mrs Michael D Towers
LaDona M Welch
Mrs Pearl Yu
Ann U Stout MD
Carmelita R Tri
Dr & Mrs Richard G Weleber
Mr & Mrs Jack Zidell
J Timothy Stout MD
Darlene M Tri
WELfund Inc
Mr & Mrs Carl W Zikeli
Mr & Mrs Sam L Stovall
Glenn L Tri
Mr & Mrs Grover Welty
Marvin Zink
Suzanne R Strahan
Patricia A Tritz
Bettie Wennevold
Susan L Ziolko
Mr & Mrs Wesley C Strahm
Louise Tucker
Rita West
Mr & Mrs Robert E Zuck
Mr & Mrs Gregory T Straub
Toshikiyo Uchida DMD*
Mr & Mrs Jack A Westing
Mr & Mrs Gary E Zumwalt
Cynthia S Strawn
Muriel K Unkeles
Mr & Mrs Chris L Wheeler
Faith R Strong
Mr & Mrs Thomas R Uphaus
David Timothy Wheeler MD
Juanita B Struble
Barbara Uyesugi
Mr & Mrs Eldridge H White
Margaret M Sudduth
Mr & Mrs George Van Biber
Leal Daly Whittlesey
Eric B Suhler MD
Mr & Mrs L E Van Buskirk
Mrs Louise C Wicks
Scot A Sullivan MD
David N Van Camp
Noel F Wicks*
Mr & Mrs Herbert H Sundby
Kenneth F Van Duyn
Marta Widman
Sharon A Susanka
Jane Van Dyke
Barbara J Wilkins
David C Sutherland
Mr & Mrs David Vanasche
Jane H Wilkins
Dr Kenneth C Swan Fund at
George N Vigeland Jr MD &
Cora Wilkinson
Oregon Community Foundation
Karen M Vigeland MD
Mr & Mrs Gary E Will
Dr & Mrs Kenneth C Swan
Charles A Viltz
Dr & Mrs Elvin T Williams
Mr & Mrs Barry J Swanson
Mr & Mrs Gary C Vogel
Mr & Mrs J Robert Williams
Mr & Mrs Wallace J Swanson
Paul R Vogt CPA
Mr & Mrs Raymond C Williams
Swedish Society Linnea
Mr & Mrs Phillip F von Feldt
Mr & Mrs Dain A Wilmarth
A William Sweet
Mr & Mrs James Voytko
David J Wilson MD
Virginia Sweetland
Mr & Mrs Robert Wack
Reverend & Mrs Doyle E Wilson
Leslie J Swope USA Ret
Joelle K Waddle
James H Winkler
Darl L Synoground
Dennis S Wagner DMD
Jeanne L Winn
Margaret J Taft
Karol C Wagner
Lawrence Winthrop
Mary A Talbott
Dorothy Waite
Dr & Mrs Calvin Wipf
James A Tammaro MD
Mr & Mrs H G Waite
Richard G Wirtz
Stephen G Tandy
Dr & Mrs James R Waldman
Mr & Mrs Richard Witzany
Dr & Mrs Eugene E Taylor
Mary M Walker
Gabriel Wolff
Mr & Mrs John C Taylor Jr
William T Walker
Women of the Moose # 1184
Mr & Mrs Randy L Taylor
Mr & Mrs Dennis H Wallace
Mr & Mrs Bruce L Wong
S H & A M Tebbets Estate
Patricia Wallace
Mr & Mrs John S Wood Jr
Margaret E Teufel
Mr & Mrs Henry J Wallaert
John W Wood MD
Oregon Community Foundation
40
C a s e y Ey e In s t i t u t e Re s o u r c e s a n d Re f e r r a l Se r v i c e s
INFORMATION & COMMUNITY SERVICES
503.494.3000
ADMINISTRATION
503.494.7890
Fax: 503.494.4286
LOW VISION SERVICE
503.494.3098
Fax: 503.494.2282
CODING AND COMPLIANCE
503.494.6107
Fax: 503.494.6864
NATIONAL REGISTRY OF DRUG
INDUCED OCULAR SIDE EFFECTS
503.494.5686
Fax: 503.494.4286
CONTACT LENS SERVICE
503.494.5536
Fax: 503.494.5372
COUNSELING/SOCIAL
SERVICES
503.494.1618
Fax: 503.494.5347
DIAGNOSTIC OPHTHALMIC
ECHOGRAPHY
503.494.7693
Fax: 503.494.5188
ELECTRORETINOGRAPHY
SERVICE
503.494.8386
Fax: 503.494.5347
ELKS LIAISON
503.494.3557
Fax: 503.494.2282
NORTHWEST CENTER
FOR EYE ALIGNMENT
503.494.1952
Fax: 503.494.5347
OPTICAL SERVICES
503.494.3030
Fax: 503.494.0588
ORTHOPTICS
503.494.4961
Fax: 494.5372
PHARMACY
503.494.3933
Fax: 503.494.0048
PATHOLOGY
503.494.7881
Fax: 503.494.7233
PHOTOGRAPHY
503.494.7693
Fax: 494.5188
EYE BANK
503.413.7523
KENNETH C. SWAN LIBRARY
503.494.3380
MACULAR DEGENERATION
CENTER
503.494.3537
Fax: 503.494.7233
SURGERY SCHEDULING
503.494.3943
Fax: 503.494.3349
VISUAL FIELD AND HRT STUDIES
503.494.7667
Fax: 503.494.3017
WEBSITE: www.ohsucasey.com
This 2002 Casey Eye Institute Annual Report was produced by the Oregon Health & Science Unversity Department of Ophthalmology
at the Casey Eye Institute.
Co-Editors and Writers: Genevieve Long, Ph.D., Nancy Mitchell, B.A., C.O.T., Joan Randall, MPH
Designer: Buck Winston
A special thanks to the Casey Eye Institute Ophthalmic Photography Department.
Photographers: Mark Evans, Chris Howell, Peter Steinkamp, Pat Wallace
C A S E Y
3 3 7 5
S . W.
T E R W I L L I G E R
E Y E
B LV D .
I N S T I T U T E
P O R T L A N D ,
O R E G O N
9 7 2 3 9 - 4 1 9 7